Synergizing angiogenesis and osteogenesis in a smart bone substitute by Alfayez, Eman Saud
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 


















and osteogenesis in a smart 










Tissue Engineering and Biophotonics Division 
Dental Institute 
















The major aim of this project was to develop a biologically active bone scaffold that 
could induce vascularization in critical-size defects (CSD) and hence bone formation.  In 
this study, functionalization of three-dimensional (3D) printed biphasic calcium 
phosphate (BCP) scaffolds was investigated.  The first functionalization approach 
involved printing scaffolds with two different pore geometries and sizes; square (400µ) 
and round (800µ).  The second was by coating scaffolds with DAR16-II; a self-assembly 
peptide that forms a hydrogel nanostructure mimicking extracellular matrix (ECM).  A 
rabbit model was used to study these functionalization methods; square and round pore 
scaffolds with and without DAR16-II coating were implanted into experimental rabbit 
calvaria bone CSD defects.  After 8 weeks, animals were killed and tissue was processed 
for histomorphometric analysis.  Histological evaluation showed that bone formation was 
pore size and geometry independent while DAR16-II was successful in inducing bone 
formation compared to non-coated scaffolds.  The following in vitro studies aimed 
towards understanding the basic cell response that enhanced bone formation in vivo.  
Human mesenchymal stem cells (MSCs) were used to identify the osteogenic potential of 
DAR16-II.  Molecular analysis and mineralization staining showed that DAR16-II lacks 
osteoinductive properties.  However, DAR16-II preserved cell viability when used as a 
BCP coating in vitro.  In addition, DAR16-II exhibited angiogenic potential upon 
culturing with human umbilical vein endothelial cells (HUVECs) in vitro.  DAR16-II 
induced the spreading of endothelial cells, activation and tubular-structure formation.  
Angiogenesis Real time-2 (RT2) polymerase chain reaction (PCR) array was used for 
gene expression analysis and showed that DAR16-II angiogenic effect was regulated by 
overexpression of endoglin (ENG or CD105), a clade E member of the serine protease 
inhibitor-1 (SERPIN-1) and β-Actin (ACTB) and down-regulation of VEGF receptor I 
(Flt1) and VEGF receptor II (KDR) Flt1.  Furthermore, DAR16-II enhanced attachment 
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of monocyte THP-1 cells.  Results have demonstrated that DAR16-II add a proactive 
factor to BCP scaffolds.  The proposed functionalization methodology increases the 
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1.1 Introduction  
 
Bone is the major structural supportive connective tissue of the body.  It is a rigid organ 
that constitutes the skeleton.  It provides support and protection to internal organs, allows 
movement and harbours the haematopoietic compartment, which produces blood cells.  
Bone is composed of collagen fibres and inorganic bone mineral in the form of small 
spicules.  It has different shapes and sizes with variable internal and external structures.  
Bone is metabolically active and remodels constantly throughout the whole lifetime of an 
individual.  Turnover warrant adaptation of the skeleton, preserves its function, and 
allows healing of bone upon damage.  In this process, bone forming cells (osteoblasts, 
OB) of mesenchymal origin and bone resorbing cells (osteoclasts, OC) of myeloid origin 
resorb and appose new bone in a tightly regulated way.  During bone repair upon injury 
these mechanisms are activated to restore lost bone.  These mechanisms are also active 
during the repair of small bone defects.  This involves the formation of a primary callus 
providing a provisional matrix for bone repair.  Invasion of this matrix by neo-formed 
blood vessels guide and drive the migration and differentiation of osteogenic precursors.  
As these cells fully differentiate into osteoblasts they lay down new bone matrix to restore 
the lost hard tissue.  With the increase in aging population, prevalence of sport related 
traumas, accidents, tumours and pathological conditions such as osteoporosis all increase 
the demand of bone related interventions to repair or replace damaged bone.  Indeed, 
when the size of the defect extends beyond the intrinsic regenerative capacity of bone, 
reconstruction is required.  
 
Autologous bone grafts are the gold standard method for reconstructing bone tissue.  
Autologous bone comprise cells, signalling molecules, extracellular matrix (ECM), 




transplantation (Dimitriou et al., 2011).  In the case of large defects, the additional step of 
harvesting bone from the donor site prior implantation is a major drawback for this type 
of graft as it increases the patient’s pain, discomfort, risk of infection and time of the 
procedure.  In addition, the limited availability of bone tissue that can be grafted has led 
to the use of exogenous grafts including xenografts, allografts and synthetic grafts (De 
Long et al., 2007).  Still the absence of cells and biological cues in these grafts limit their 
healing potential to osteoconduction only by supporting cells migrating from the 
boundaries of the defect site to form new bone.  One major drawback of the current 
grafting materials is the insufficient ingrowth of blood vasculature from the host, which in 
turn is necessary to promote new bone formation and the healing of the defect. 
 
To promote vascularization and subsequent osteogenesis upon graft implantation, 
different types of cells and biological active agents have been used to functionalize 
scaffolds.  Various co-culture models of endothelial, osteogenic and stem cells were used 
to pre-vascularize scaffolds before implantation.  Although enhanced vascularization and 
bone formation were achieved, the use of cells to functionalize scaffolds is far from the 
clinical application.  As the size of the defect increases, more cells are needed to seed the 
scaffold and more time is required.  Biological agents were added to scaffolds as an 
alternative to cells prior implantation in order to induce specific cell response and 
enhance bone healing.  Two types of biological agents have been used including 
morphogens and growth factors (GFs).  Morphogens (e.g. Bone morphogenic proteins 
(BMPs)) act by altering the cellular phenotype while growth factors have mitogenic and 
chemotactic properties such as vascular endothelial growth factor (VEGF) (Cochran and 
Wozney, 1999, Smith et al., 2008).  However, the major drawback of using these agents 




These agents are subjected to enzymatic degradation, dilution and rapid absorption at the 
defect site (Curry et al., 2016). 
 
Hence there is a growing need to develop a practical and sustainable method to 
functionalize scaffolds.  The main aim of adding these factors is to incorporate a 
chemotactic element that attract the host undifferentiated cells at the healing site and 
induce their osteogenic differentiation.  Since angiogenesis temporally precedes 
osteogenesis, it is pivotal to incorporate factors that can induce vascularization within 
implanted scaffolds (Carano and Filvaroff, 2003).  Vascularization is essential for 
successful bone regeneration as angiogenesis and osteogenesis are coupled throughout the 
natural bone healing process.  In early stages of bone healing, angiogenic growth factors 
induce sprouting microvessels which recruit osteoblasts and osteoprogenitor cells to the 
healing site (Gerber and Ferrara, 2000).  In the late phase of bone healing, vascularization 
and mineralization are synchronized and disruption of vascularization result in defective 
bone formation (Ivkovic et al., 2003, Kanczler and Oreffo, 2008).  Therefore, developing 
a biocompatible scaffold with customized properties such as internal geometry and 
porosity can be a key factor in cell infiltration and blood vessels formation.  In addition to 
scaffold geometry, adding a proactive factor that can enhance endothelial cells 
recruitment and differentiation is essential to form fast growing and stable vasculature to 










1.2 Bone biology  
1.2.1 Bone structure 
 
A typical mature bone is composed of two types of structures; cancellous and cortical.  
The cortical/compact bone forms the outer shielding layer comprising 80% of the total 
bone mass and its strength protects the inner cancellous/spongy bone.  Cancellous bone 
has a honeycomb structure and accounts for the remaining 20% of the bone mass and 
contains bone marrow, which is rich in stem cells (e.g. mesenchymal, haematopoietic and 
pluripotent stem cells), hence this explains the high metabolic activity in comparison to 
the cortical bone (Parfitt, 2001).  Both types are composed of the same matrices, however 
their physiological properties differ because of the different density, metabolic activity 
and bone structure (Mellon and Tanner, 2012).   
 
Microscopically, bone is composed of two types; primary (woven) bone and secondary 
(lamellar) bone.  Woven bone is the first stage of bone development during embryonic 
life and early stages of bone healing.  This type is composed of weak disordered collagen 
fibril, which is replaced during growth and late stages of bone healing with lamellar bone 
(Figure 1.1).  On the other hand, lamellar bone is strong and highly organized as it is 
made of compact collagen fibrils running parallel in sheets containing osteocytes and 
bone matrix. Lamellar bone is presented differently in the cortical and cancellous portions 






Figure 1.1 Bone anatomy.  The outer compact bone is composed of osteons (Haversian 
system).  This Haversian system is made of concentric lamellae and central (Haversian 
canal) contains blood vessels, lymphatic and nerves.  Cancellous (spongy) bone is trabecular 
in structure and is highly vascularized (Adapted from www.liebertpub.com/teb, 2004 
Pearson Education,Inc., publishing as Benjamin Cummings). 
 
 
In the cortical layer, this lamellar bone is presented in the form of osteons consisting of 4-
20 concentric sheets of lamellae with a central duct called the Haversian canal.  This 
canal is running through the centre of the osteon and contains blood vessels, lymphatics 





Whereas in the cancellous portion, lamellar bone is trabecular and arranged in 
semicircular shapes known as “packets”.  Its trabecular structure, richness of cells and 
vascularity is translated through its high metabolic activity in comparison to cortical bone 
(Jepsen, 2009). 
 
The outer bone surface is covered with periosteum, which consists of two layers: an 
external layer devoid of cells that attach to joints or bones and inner cambium, which 
contains osteoprogenitor cells and a vascular plexus.  The latter is connected to the 
endosteum and marrow space with small channels called Volkman’s canals which 
transport blood and nutrients to the osteons (Buckwalter et al., 1995). 
 
1.2.2 Bone matrix 
 
Bone is a remarkable dynamic and hierarchical tissue.  Its extracellular matrix (ECM) is 
composed of inorganic and organic components.  This matrix has a major impact in 
determining bone properties.  The inorganic component provides bone with strength and 
stiffness while the organic part provides toughness due its spongy nature (Burr, 2002).  
60-70% of this matrix is composed of inorganic hydroxyapatite (HA) mineral 
[Ca10(PO4)6(OH)2], remaining matrix is composed of organic proteins, where collagen 
type I (Col1) is the main constituent, and water (Sommerfeldt and Rubin, 2001, 
Bilezikian et al., 2008) (Table 1.1).  Previously, the mineral phase was considered the 
main component that affect the bone mechanical behaviour with its high elastic modulus 
(~100 GPa) providing bone with its rigidity and anisotropic behaviour (Hasegawa et al., 
1994).  However, currently the collagen phase is considered a significant factor in bone 
biomechanics.  Leng et al. have reported in his research that as the Young’s modulus of 




collagen phase in cortical bone decreased respectively (Leng et al., 2013).  Also, water 
was found to play a crucial role in maintaining bone’s mechanical properties.  This was 
demonstrated by drying bone at different temperatures, loss of water resulted in increased 
stiffness while strength and toughness were decreased respectively (Nyman et al., 2006).    
 
Organic matrix proteins Function 
Collagen I Matrix calcification 
Osteonectin Bone mineralization 
Fibronectin Osteoblast attachment 
Osteopontin Bone remodelling 
Osteocalcin Bone remodelling 
 
Table 1.1 Some of the bone organic matrix proteins and functions.   
 
1.2.3 Bone cells 
 
Osteoprogenitor cells that differentiate into osteoblasts and osteocytes originate from 
mesenchymal cell lineage while osteoclasts originate from hematopoietic lineage (Boyle 
et al., 2003, Pittenger et al., 1999).  The interaction of these three cells results in bone 
development and homeostasis.  Table 1.2 summarize the morphological characteristics 
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Figure 1.2 Osteoblasts differentiation progression and corresponding transcription factors.  
Glucose initiates osteogenic differentiation via Glut1 glucose transporter.  A cascade of gene 
expressions follow Glut1 including: runt-related transcription factor 2 (Runx2), osterix 
(Osx), collagen type I (Col1) and osteocalcin (OCN).  Each gene expression corresponds to a 
specific osteoblast maturation stage until osteoblasts become osteocytes and secrete 
sclerostin protein (Adapted from Maes et al., 2010b, Wei et al., 2015). 
 
OB differentiation (Figure 1.2) is initiated by glucose uptake through an insulin-
independent mechanism facilitated by Glut1glucose transporter.  Glut1 expression is 
required for OBs to express Runt-related transcription factors 2 (Runx2) (Wei et al., 
2015). Runx2 is considered the principle transcription factor in OBs differentiation 
followed by Osterix (Osx) gene expression during skeletogenesis (Nakashima et al., 




ECM protein Col1 (Marie, 2008).  Next, OBs mineralize ECM and express osteocalcin 
(OCN).  Finally, OBs become embedded in the mineralized ECM and differentiate into 
osteocytes (Karsenty and Wagner, 2002). 
 
When OB progenitor cells express Runx2 and Col1 they enter a proliferation phase in 
which cells display alkaline phosphatase (ALP) activity and become preosteoblasts 
(Capulli et al., 2014).  Once these cells express Osx and secrete bone matrix proteins such 
as OCN and bone sialoproteins I/II (BSP I/II) they are considered mature OBs 
(Nakashima et al., 2002, Florencio-Silva et al., 2015).  
 
1.2.4 Matrix formation  
 
OBs deposit woven organic matrix (osteoid) by secreting three main constituents; 
collagen proteins (mainly type I), non-collagen protiens (OCN, osteopontin and BSP II) 
and proteoglycans (decorin and biglycans).  Mineralization of this organic matrix starts 
with a vesicular phase when the apical domain of OBs secretes approximately 100 nm 
matrix vesicles into the organic matrix (Anderson, 2003).  These vesicles bind to organic 
components, negatively charged sulphated proteoglycans immobilize positively charged 
calcium ions within the matrix vesicles.  Once OBs secrete degrading enzymes and 
calcium ions are freed from proteoglycans, they cross the calcium channels of the matrix 
vesicle membrane (Arana-Chavez et al., 1995).  When OBs secrete ALP which degrade 
phosphate containing compounds and release phosphate within the vesicle, calcium and 
phosphate ions nucleate within the matrix vesicles forming HA crystals (Glimcher, 1998).  
The second phase of mineralization which is known as fibrillar phase takes place when 
excess calcium and phosphate ions rupture the matrix vesicles and HA crystals diffuse 




develop new bone.  On the other hand, osteoclasts remodel bone by resorbing woven 
matrix to form a highly organized structure with fibres running parallel to applied forces 
(Gaston and Simpson, 2007). 
 
1.3 Types of bone growth 
 
Two types of ossification lead to bone development; intramembranous and endochondral 
ossification.  Endochondral bone formation starts with MSCs condensations that 
differentiate into chondrocytes.  These primary cartilage cells form a cartilaginous matrix 
by secreting type II collagen, aggrecan and express SOX9 along with other transcription 
factors (Kronenberg, 2003).  The cartilage enlarges in response to chondrocyte 
proliferation and matrix formation.  Chondrocytes located in the centre of the cartilage 
enlarge and hypertrophy and start to secrete collagen type X.  Hypertrophic chondrocytes 
start the mineralization phase by secreting angiogenic factors such as VEGF to attract 
blood vessels.  Hypertrophic chondrocytes recruit chondroclasts (cells from macrophage 
lineage) to digest the matrix and induce perichondral cells to differentiate into osteoblasts.  
These hypertrophic chondrocytes undergo apoptosis and osteoblasts use the cartilage 
matrix as a scaffold to lay bone matrix.  This type of bone growth is restricted to skeletal 
bone development and bone healing while development of skull flat bones is achieved 
through intramembranous ossification.  In intramembranous ossification, MSCs 
condensations differentiate directly into osteoblasts and produce bone matrix rich in Col1.   
 
It was found that MSCs isolated from craniofacial sutures (SuSCs) were superior to 
MSCs isolated from the bone skeleton in terms of self-renewing, differentiation potential 
and clonal expansion (Maruyama et al., 2016).  SuSCs exclusively express Gli1+ and 
Axin2 and induce bone formation by intramembranous ossification (Zhao et al., 2015, 




were reconstructed with craniofacial skeletal grafts compared to grafts harvested from 
endochondral bones in both volumetric maintenance and survival rate (Phillips et al., 
1992).  
 
1.4 Angiogenic/Osteogenic coupling 
 
In both types of bone ossification, vascularization maintain skeletal homeostasis by acting 
as a communication and transportation system for all essential factors and circulating 
cells, therefore impairment of blood supply results in skeletal pathological conditions 
such as osteonecrosis (Childs, 2005).  In addition, the vascular system acts as an 
angiocrine organ during healing by generating tissue specific-angiocrine factors and 
initiate the repair process to maintain homeostasis (Rafii et al., 2016).  It was found that 
in postnatal long bone, specialized bone vessels; types H and L, regulate osteoblasts and 
chondrocytes differentiation (Kusumbe et al., 2014, Ramasamy et al., 2014).  Type H 
vessels include columnar tubes and arches located in the bone metaphysis and endosteum.  
While type L is the extension of type H vessels in the diaphysis and forms sinusoidal 
vessels within the haematopoietic bone cavity.  Osteoprogenitors expressing Osx, Col1 
and Runx2 selectively arrange themselves around type H vessels.  Blind-ends of type H 
vessels are closely positioned to the growth plate chondrocytes in the metaphysis (Figure 
1.3).  As chondrocytes produce VEGF-A; the main specific mitogen for endothelial 
growth, the Noggin expression is stimulated by endothelial Notch signalling.  Noggin 
promotes osteogenesis and angiogenesis by monitoring osteoprogenitors differentiation 
and chondrocytes hypertrophy (VEGF-A source).  This angiocrine pathway couples 







    
 
 
Figure 1.3 Osteogenesis and angiogenesis coupling in postnatal long bone by signalling 
interaction between chondrocytes, ECs and osteoprogenitor cells.  Type H vessels which are 
embedded in the metaphyseal bone trabeculae are connected via arches at the distal end.  
These arches extend into the growth plate chondrocytes and receive VEGF-A which is an 
essential factor for angiogenesis.  Notch signalling promotes the expression of endothelial  
Noggin which is required for perivascular osteoprogenitors differentiation and hence 
osteogenesis.  Also, endothelial Notch and Noggin expression modulate chondrocyte 
maturation and hypertrophy which regulate VEGF-A expression and thereby angiogenesis 
(Adapted from Ramasamy et al., 2014). 
 
 
1.5 Vascularization in bone healing 
 
In small size defect, bone can self-repair and heal through three phases (Figure 1.4); the 
inflammatory phase, the repair phase and the remodelling phase (Jin et al., 2015).  
Vascularization plays a crucial role in the healing process by forming a haematoma 




macrophages into the bone in the inflammatory phase.  This results in granulation tissue 
development, vascular tissue ingrowth and migration of MSCs and Endothelial cells 
(ECs) to healing site.  This granulation tissue is replaced by fibrous tissue during repair 
phase and supports the vasculature ingrowth.  Next, external callus is formed by direct 
bone formation while internal callus is formed by MSCs chondrogenic differentiation.  
During the healing process, the periosteum is recognized as a key element in the bone 
repair process.  Its internal layer is highly vascularized and predominantly composed of 
progenitor cells.  These cells include osteoblasts that deposit new bone matrix and 
pluripotent cells that migrate to the healing site and differentiate to regenerate bone 
(Ozaki et al., 2000, Colnot, 2009).  Osteoblasts recruited to the fracture site calcify the 
cartilage matrix of the internal callus and form mineralized woven bone matrix.  During 
remodelling phase, woven bone is remodelled into stronger lamellar bone by osteoclastic 
resorption of the callus.  Finally, the healing bone restores the original bone shape, 
structure and function (Jin et al., 2015). 
 
 
Figure 1.4 Schematic of the fracture healing.  The three distinct but overlapping healing 
stages: the inflammatory, the repair and the remodelling phases.  Haematoma is developed 
to start the healing process in the inflammatory phase. Followed by soft 
callus/unmineralized cartilage formation. After that, fibrous tissue is formed and followed 
by hard callus formation/secondary bone.  Finally this hard callus is remodelled and lost 




1.7 Bone scaffolds 
 
Critically sized bone defects going beyond the endogenous regenerative potential require 
the utilisation of grafting scaffolds to promote healing.  Autografts are still considered the 
gold standard scaffolds for bone replacement.  However, shortcomings included 50% 
failure rate in non-union treatments, limited tissue available for grafting and the second 
surgical site morbidity involvement (Brighton et al., 1995, Clavero and Lundgren, 2003).  
As an alternative, allografts (grafts transplanted from a donor from the same species) 
were used for bone replacement.  Still, two main drawbacks were associated with this 
type including significant loss of strength with 30-60% failure rate over 10 years of 
implantation and late rejection tendency (Wheeler and Enneking, 2005, Finkemeier, 
2002).  On the other hand, the use of Xenografts (grafts transplanted from a donor of 
different species) for bone replacement is far from ideal candidate due to the difference in 
physiological structures and function from human bone (Goldstein, 2002). 
 
Taking into account the limitations of available bone grafts, there is an increase need for 
developing tailored engineered bone scaffolds that mimic the lost bone structure and 
facilitates the healing process.  An ideal scaffold for bone tissue engineering should 
mimic natural bone, promote endogenous repair mechanisms and eventually degrade over 
time leaving space for natural neo-formed bone.  Scaffold structure and composition can 
play a major role in this crucial process since one of the primary functions of a scaffold is 
providing mechanical stability upon implantation.  Furthermore, scaffold structure must 
be osteoconductive, promoting the recruitment of host cells.  Bone engineering is mainly 
dependant on four basic elements presented in Figure 1.5; 1) a scaffold which act as the 
backbone in which new tissue will develop, 2) cellular component to initiate bone 




differentiation and 4) vascularization in order to drive formation of new bone and then to 
maintain cellular homeostasis.  
 
Figure 1.5 Basic factors of engineering tissues; potential combinations and their interaction. 
1) Scaffold is the key player in the regeneration process as it acts as a template for new 
tissue formation.  It can be fabricated from a single natural (e.g. Collagen) or synthetic 
(ceramic) material or a composite of different materials in order to enhance mechanical and 
biological functions. 2) Cellular component from a single cell source or a co-culture of 
different types of cells to induce bone formation.  3) Signalling biomolecules to activate the 
cellular response to the implanted scaffold during bone regeneration. 4) Vascularization 







1.7.1 Scaffold material 
1.7.1.1 Natural  
Polymers purified from plants and animals including collagen, chitosan and glycosasmino 
glycans (GAGs) have been extensively used in the vast body of bone engineering 
research as a natural scaffold material (Harley and Gibson, 2008, Minuth et al., 2010).  
These materials are composed of natural components of ECM and they contain specific 




As collagen is the most abundant protein in bone matrix and a biocompatible material, it 
has been widely used in bone engineering (Glowacki and Mizuno, 2008).  It induces 
differentiation of osteoprogenitor cells into osteoblasts and osteoblast maturation into 
osteocytes via transmembrane alpha (2) beta (1) integrin receptor interaction (Chen et al., 
2007, Mullen et al., 2013).  Also, it was found that the addition of GAGs to collagen 
structure augments its osteogenic capacity (Farrell et al., 2006, Keogh et al., 2010).  
However, its use in bone engineering is limited by its inadequate mechanical properties.  
Chemical crosslinking is the commonly used method to improve its mechanical strength 
(Charulatha and Rajaram, 2003).  For example, augmenting the use of photochemical 
crosslinking via riboflavin (a non-toxic photoinitiator) with plastic compression method 
enhanced Young’s modulus of collagen by 2.5 fold compared to non-crosslinked collagen 




Gelatine is a modified form of collagen; it has a denatured structure and has been used in 




osteogenic differentiation of bone marrow-derived MSCs in cranial defects of athymic 
nude mice models (Ben-David et al., 2011).  However, collagen-based scaffolds lack the 
required mechanical properties for bone replacement (O'brien, 2011). Modifying collagen 
cross-linking in order to improve mechanical stiffness has been investigated (Tierney et 
al., 2009, Haugh et al., 2009, Bailey et al., 2011, Haugh et al., 2011).  Still scaffolds lack 
the required mechanical stiffness to replace bone in load bearing areas.  Furthermore, the 
core degradation at the centre of collagen glycosaminoglycan (CG) scaffolds in in vitro 
culture raised the concern of the long term sustainability of collagen-based scaffolds 




Alginate is a polysaccharide extract from brown algea and has been studied for its 
application in bone engineering (Alsberg et al., 2001, Sun and Tan, 2013).  Its porosity 
and the feasibility in changing its chemical structure permit cellular interaction and 
controlled release of cells and growth factors (Quinlan et al., 2015).  It has been used as a 
carrier for BMP-2 and angiogenic factors to enhance bone regeneration and 
vascularization (Boerckel et al., 2011, Freeman and Cohen, 2009).  In order to use it for 
bone replacement it has to be combined with a supporting material such as chitosan and 
hydroxyapatite (HA) to enhance its strength and improve osteogenic differentiation in the 
healing site (Li et al., 2005, Turco et al., 2009, He et al., 2012).  
 
d. Chitosan 
Chitosan is also a polysaccharide that is derived from chitin found in crustaceans and 
coral (Di Martino et al., 2005).  It is a biocompatible, biodegradable and porous 
antimicrobial material (Venkatesan and Kim, 2010).  Similar to previously mentioned 




properties.  Recently, fresh water fish scales have been studied as a source of biological 
porous hydroxyapatite (Hap) and a possible bone replacement material (Panda et al., 
2014).  However, it was demonstrated that they carry the risk of infection in addition to 
the common disadvantage of all natural derived scaffolds represented in the poor 
mechanical strength (Vuola et al., 2000, Ivankovic et al., 2010, Battistella et al., 2012). 
 
1.7.1.2 Synthetic  
1.7.1.2.1 Polymers  
 
Poly-ε-caprolactone (PCL) has been used in bone engineering for its mechanical 
properties, porosity and biodegradability (Ekaputra et al., 2011, Cipitria et al., 2013).  Its 
porosity allows cellular cross-talk and integration thus supports osteogenic and 
angiogenic mechanisms across its structure (Kyriakidou et al., 2008, Mitsak et al., 2011).  
One of the main drawbacks of PCL is hydrophobicity and subsequent low surface energy 
which affect its use in tissue regeneration.  In order to enhance PCL cellular interaction, 
surface functionalization was investigated by using different materials such as  plasma 
treatment and double protein coating of gelatine B and fibronectin which effectively 
induced cell adhesion, proliferation and tissue formation (Jacobs et al., 2013, Declercq et 
al., 2013).   
 
Polyethylene glycol (PEG), another type of synthetic polymer, also can be functionalized 
to induce bone regeneration with integrin-specific peptides, growth factors and 
polysaccharides (Shekaran et al., 2014, Pratt et al., 2004, Rizzi et al., 2006).  However, 
the poor mechanical properties and the need for a supportive material limit the use of 






1.7.1.2.2 Bioactive glasses and ceramics  
A .Bioactive glasses 
 
Bioactive glasses are calcium- and possibly- phosphate containing silica glasses that 
produce a bioactive hydroxycarbonate apatite layer once immersed in a biological fluid.  
It can be engineered to control ion release and stimulate specific gene transduction 
pathways to enhance osteogenic differentiation (Hench and Polak, 2002, Jell and Stevens, 
2006).  It is a porous and biocompatible material which facilitates cellular integration and 
maintain cells viability (Jones and Hench, 2004).  Its brittleness is the main drawback for 
its use as a bone replacement material.  However, Chen et al. in a recent study 
incorporated a novel p(N-isopropylacrylamide-co-butyl methylacrylate) (PIB) nanogels 
with bioactive glass scaffolds and improved scaffolds mechanical properties and 
promoted bone formation in critical-size femur defect of mature osteoporotic female 
Wistar rats in vivo (Chen et al., 2015b).  In addition, coating with polylactic-co-glycolic 
acid (PLGA) induced human mesenchymal stem cells (hMSCs) proliferation and 




 In addition to bioactive glasses, ceramics are considered attractive materials in bone 
engineering because of the resemblance of their chemical composition to the bone 
mineral phase.  Ceramics contain calcium and phosphate as basic structures; HA and 
tricalcium phosphate (TCP) are the commonly used types as bone scaffolds (LeGeros, 
2002, LeGeros, 2008).  Ceramics are biocompatible; osteoconductive materials which 
osteointegrate via chemical bonds in the healing site to encourage new bone formation 
(Kim et al., 2014a, Cambra-­‐Moo et al., 2014).  The major disadvantage of ceramic is its 
inherent brittleness hence rendering its use to non-load bearing areas (Cardoso et al., 




research in addition to bone engineering.  Although different materials were used in 
conjunction to ceramics in order to enhance mechanical properties of fabricated scaffolds, 
compressive strength and toughness were far below the normal bone values of fracture 
toughness of 2–12 MPa · m1/2 and compressive strength of 130–180 MPa (Wang and 
Shaw, 2009, Fielding et al., 2012, Gao et al., 2014).  Developing an effective method to 
overcome this limitation is essential as ceramics are becoming the material of interest in 
3D printing and have showed promising results in cell proliferation and osteogenic 
differentiation by controlling pore sizes, surface topography and grain size (Alenezi et al., 
2013).  For example, calcium phosphate (CaP) scaffolds composed of TCP, polyethylene 
glycol and trisodium citrate were 3D printed at room temperature and implanted in a 
sheep model in vivo (Bergmann et al., 2014).  Superior mineral density was detected with 
3D printed scaffolds compared to control autografts.  The significance of using such 
techniques in addition to the above-mentioned advantages is the possibility of using 
ceramics as viable carriers of bioactive molecules like BMP’s, growth factors and drugs 
without undergoing denaturation because of the heat needed in sintering ceramics. 
 
1.7.2 Scaffold design 
1.7.2.1 Scaffold architecture 
 
Bone scaffolds act as a transient skeleton or template for cells to infiltrate and attach 
during the healing process.  Scaffold architecture can facilitate the bone formation and 
vascular growth by adjusting the pores size, porosity and interconnectivity.  The pores 
network is essential for metabolites exchange and cellular cross-talk (Lee et al., 2010).  In 
addition, in bone engineering, porosity is essential for osteoblast infiltration and 
osteogenic differentiation (Kasten et al., 2008).  Kuboki et al. showed that HA porous 




detected with non-porous scaffolds (Kuboki et al., 1998).  The scaffold porosity can be 
adjusted in order to enhance specific cellular responses.  Bone formation is linked to the 
degree of scaffold porosity with favourable results associated with 70-93% porosity 
(Kruyt et al., 2003, Roy et al., 2003, Takahashi and Tabata, 2004).   
 
A. Pore size 
 
The pioneering work of Hulbert et al. demonstrated the effect of pore size on bone 
regeneration by using calcium aluminate cylindrical pellets with 10-200 µm pore sizes in 
dog femoral defects (Hulbert et al., 1970).  Pores with smallest sizes <75 µm, resulted in 
fibrous tissue formation while medium sized pores 75-100 µm resulted in unmineralized 
osteoid tissue formation.  Large pores >200 µm enhanced both bone ingrowth and 
vascular formation.  Kuboki et al. showed that larger pores ranging from 300 to 400 µm 
induced more bone formation in HA scaffolds implanted subcutaneously in rats (Kuboki 
et al., 2001).  The enhanced bone formation was explained by the rapid vascular 
ingrowth.  Bai et al. confirmed the importance of pore size on blood vessels formation by 
implanting beta-tricalcium phosphate (β-TCP) scaffolds with different pore sizes in a 
rabbit model (Bai et al., 2010).  Scaffolds with pore sizes smaller than 400 µm restricted 
blood vessels growth while increasing the pore size beyond this value had no significant 
difference on scaffold vascularization.  They proposed that the optimal pore size for blood 
vessels formation is 400 µm.  
 
B. Pores interconnectivity  
 
Pore interconnectivity has a crucial role during healing as it facilitates nutrient and 
oxygen delivery as well as waste removal (Kim et al., 2010).  In addition, increasing pore 




of developed blood vessels during healing (Bai et al., 2010).  Moreover, bone formation 
was found to be affected by pore interconnectivity.  Uebersax et al. studied the effect of 
pores interconnectivity on MSCs seeded in silk fibroin scaffolds (Uebersax et al., 2006).  
They found that higher interconnectivity resulted in a homogenous mineralization and 
bone formation.    
 
1.7.2.2 Scaffold fabrication techniques  
 
Conventional approaches of fabricating 3 dimensional (3D) scaffolds include salt 
leaching, gas foaming, emulsion/freeze drying and expansion in supercritical fluid 
(Chung and Park, 2007).  It is difficult to control scaffold external and internal geometry 
by using these conventional methods.  They require manual handling and result in 
inconsistent reproducibility (Miranda et al., 2006).  Rapid prototyping (RP) however, also 
known as solid free form fabrication (SFF) is an advanced fabrication technique used to 
print custom-made 3D scaffolds.  By using this technique, both external and internal 
architecture of printed scaffolds can be controlled and reproduced including the pore size, 
shape and orientation (Hollister, 2005).  The main concept is to build the scaffold by 
automated extrusion of biomaterials in tomographic layer sequence based on a pre-
designed structure.  This pre-design is constructed from scanning the defect site and 
transfer scanned images to a computer program (Chang and Chiang, 2003, Soo and Yu, 
2003).  Different methods currently used in fabricating 3D scaffolds depend on the RP 
technology include; stereolithography, selective laser sintering, shape deposition 
manufacturing, fused deposition modelling and robocasting (Yang et al., 2002, Yeong et 
al., 2004, Manjubala et al., 2005, Hollister, 2005).  However, these methods showed 
limited control over printed scaffolds resolution and interconnectivity excluding 
robocasting.  Robocasting (also known as Direct Write (DW) technology) is a filament 




nozzle (Lewis et al., 2006).  The rheology of extruded inks allows them to flow steadily 
and once they are deposited, they gel and their viscosity and elastic modulus rise (Ricci et 
al., 2012).  This flow behaviour allows development of scaffolds with controlled pore size 
and interconnectivity (Smay et al., 2002, Michna et al., 2005).  In addition to the design 
control, different materials can be mixed and deposited by a multi-reservoir ink chamber 
or they can be deposited in gradient mode.  The robocasting resolution is very high and 
limited only by the nozzle diameter and very reproducible (Ricci et al., 2012).  Moreover, 
different types of inks can be used that may or may not need firing.  In the case of using 
non-firing colloidal inks such as chitosan, biological cues like growth factors can be 
added during fabrication.  While in the case of using firing colloidal inks such as biphasic 
calcium phosphate (BCP), any biological agent has to be added post-firing and adsorbed 
into the printed scaffold (Ricci et al., 2012).   
 
1.8 Vascularization as a key challenge in bone engineering 
 
A prerequisite for successful bone engineering is adequate vascularization to allow 
successful integration with host tissue.  In critical size defect (CSD), which defined as the 
smallest size defect that cannot heal spontaneously, nutrient and oxygen transport occurs 
mainly through diffusion.  This diffusion is limited to 100 to 200 µm only from the 
surrounding vasculature into the implanted scaffold (Carmeliet and Jain, 2000).  In 
addition, several scaffolds used for bone regeneration demonstrated poor angiogenic 
induction upon implantation.  This lead to the formation of insufficient vasculature to 
sustain the formation of healthy new bone and to eliminate the byproducts of the 
degrading scaffold (Mikos et al., 1993, Nomi et al., 2002).  Therefore, the accumulation 
of these byproducts interferes with the healing process and elicits inflammatory responses 
(Taylor et al., 1994).  The subsequent challenge after the development of 




(Scheufler et al., 2008).  This process can take up to one week which might result in 
ischaemia and rejection of the graft (Lokmic and Mitchell, 2008).  In order to develop a 
strategy to overcome these problems, different methods were proposed including cell 
seeding and the addition of bioactive factors.  
 
1.9 Vascularization strategies in bone engineering 
1.9.1 Scaffolds prevascularization 
 
The concept of in vivo prevascularization of grafts was applied for the first time in bone 
engineering when axial vascularization was established in solid porous constructs through 
arteriovenous (AV) loop (Figure 1.6-middle section) (Kneser et al., 2006).  In this two-
step procedure, the graft is first implanted ectopically in a vascularized mesh until a 
vascular network is developed within the graft from the surrounding vasculature.  After 
that the graft is transferred to defect site as a free flap where immediate vascularization 
can be achieved due to surgical anastomosis with the main feeding vessels in site.  
However, the two surgical procedures involved in this method and the time consuming 
factor are the main drawbacks.  
 
 Another approach of current interest is in vitro prevascularization, which counteracts the 
aforementioned drawbacks, where single surgical procedure is needed and shorter time is 
required (Rouwkema et al., 2008).  Its principle is based on seeding the scaffold with a 
single source of vasculogenic cells or a co-culture of vasculogenic and bone forming cells 
in a supportive environment to form in vitro blood vessels before implanting the graft 
(Figure 1.6, Top) (Hutton and Grayson, 2014).  This technique was used in engineering 
different types of tissues including skin, cardiac muscle, skeletal muscle and bone 




Choong et al., 2006).  Another in vitro technique is to seed the graft prior implantation 
with specialized cells, signalling molecules and factors that can induce blood vessels 
formation (Figure 1.6, bottom).  In this procedure, cell cross-talk with cells in situ can 
facilitate the cellular interaction and aggregation to form a functioning vascular network.  
Also, controlled release of specific growth factors can be achieved which enhance both 
bone and blood vessels development. 
 
 
Figure 1.6 Vascularization techniques for bone tissue engineering.  1) Top: In vitro pre-
vascularization of scaffolds by seeding cells and induce blood vessels formation by growth 
factors.  The concept is based on implanting scaffolds with engineered capillaries to 
anastomose with host vasculature and perfuse the entire scaffold.  2) Middle: In vivo ectopic 
pre-vascularization involves an extra step to the previous method.  After seeding the scaffold 
with cells, scaffold is implanted into a highly vascularized bed, such as muscle or 
arteriovenous (AV) loop, to allow extensive vascular ingrowth.  After that, the vascularized 
scaffold is transplanted as a free flap to the bone defect and surgically anastomosed with 
surrounding vessels to allow immediate perfusion.  3) Bottom In vivo orthotopic 
vascularization involves direct implantation of cell seeded scaffolds loaded with growth 
factors into the bone defect for in situ tissue development.  In this type, the vascularization 
development is mainly dependent on cell survival, endogenous cell signaling and controlled 






In an attempt to mimic the vascularized periosteum and to use it in enhancing bone graft 
survival and regenerative capacity, Kang et al. fabricated a vascularized cell-sheet-
engineered periosteum (CESP) (Kang et al., 2014).  Two cell sheets were prepared in 
which the first was composed of human umbilical vascular endothelial cells (HUVECs) 
cultured on top of hMSCs layer mimicking the fibrous layer of the periosteum.  The 
second sheet composed of mineralized hMSCs to mimic the cambium layer of the 
periosteum.  The mineralized cell layer was wrapped around β-TCP scaffold followed by 
the vascularized layer.  The engineered periosteum in vitro enhanced vascularization and 
anastomosis with the host vasculature and induced bone matrix formation in vivo (Kang 
et al., 2014).   
 
Different co-culture models were studied in vitro and in vivo in order to understand the 
order of growth factors released and how these chemicals can affect the cell-to-cell 
interactions and contribute to capillary-like structure formation.  As a general rule in 
vascularized bone engineering, cells from an endothelial source were co-cultured with 
cells from an osteogenic origin.  
 
1.9.1.1. Cell sources  
A. Endothelial cell source  
 
ECs are considered the building blocks of newly formed blood vessels during 
development and healing process.  These cells release pro-inflammatory factors and 
express cell adhesion molecules, which are necessary for the angiogenesis process and 
long-term stability by forming the inner surface of these vessels.  Primary endothelial 
cells isolated from HUVECs and human dermal microvasculature (HDMECs) are 
commonly used because of their accessibility and ease of isolation (Jaffe et al., 1973, 




fibroblast growth factor (bFGF) are required as supplements when endothelial cells are 
cultured in vitro in order to form capillary-like structures (Peters et al., 2002).  Another 
potential cell source is endothelial progenitor cells (EPCs) (Urbich and Dimmeler, 2004).  
EPCs are stem cells that have the potential to differentiate into endothelial-like cells in 
response to specific factors.  These progenitors include MSCs, adipose stem cells (ASCs), 
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPS) (Oswald et al., 
2004, Vittet et al., 1996, Choi et al., 2009, Shah et al., 2014).  EPCs are isolated and 
characterized from circulating blood and originate from haematopoietic and endothelial 
lineages.  These cells express angiogenic markers CD31+ (also known as Platelet 
endothelial cell adhesion molecule (PECAM1)) and, CD34+ or CD133+ on their surfaces 
and can develop capillary-like structures in vitro (Fuchs et al., 2010a).  The main 
advantage of EPCs over primary cells is their unlimited passaging capacity in in vitro 
culture prior differentiation into mature endothelial-like cells (Bianco et al., 2001).   
 
Primary cells in general share a limiting factor of insufficient number of isolated cells 
from the body in addition to the limited passaging potential in vitro before cells exhibit 
changes in their phenotype and start to de-differentiate.   
 
B. Osteogenic cell source  
 
Primary bone cells are OBs isolated from different bone tissues in the body and they were 
used mainly in biomaterials characterization studies (Coelho et al., 2000, Coelho and 
Fernandes, 2000).  Osteogenic progenitor cells are stem cells that differentiate into mature 
osteoblasts when cultured in osteogenic differentiation medium.  The same cell sources 
are shared between endothelial and osteogenic progenitor cells including MSCs, ASCs, 




passaging prior differentiation is shared and favoured their use in tissue regeneration over 
primary cells (Bianco et al., 2001, Kassem et al., 1997).  
 
1.9.1.2 Co-cultured cells models  
a. Endothelial cells and osteoblast cells 
 
HDMECs and OBs co-culture successfully formed capillary-like structures on cell culture 
plastic in vitro (Unger et al., 2007).  When the same co-culture model was used with 
porous 3D materials including; HA and CaP, nickel titanium and silk fibroin sheets, the 
same capillary-like structures were developed (Unger et al., 2007, Unger et al., 2010).  It 
was found that cellular-talk in this model formed microcapillary-like structures with 
lumens and stained for type IV collagen reflecting the progression of development 
(Santos et al., 2009).  In addition, significant amount of Col1 and VEGF was secreted and 
angiogenic markers such as VEGFR-2, angiopoietin-2 (ANG-2) and its receptor Tie-2 
were upregulated (Stahl et al., 2004, Santos et al., 2009). 
 
The second model of co-culturing primary cells involved HUVECs and OBs.  Capillary-
like structures were also developed on a macroporous CaP cement with Col1 and VEGF 
upregulation and CD31 and von Willebrand factor (vWF) positive staining (Thein-Han 
and Xu, 2013, Chen et al., 2014a).  Applying the same cellular model on poly 
lactide/LLA- material upregulated Insulin-like growth factor 1 (IGF-1) gene expression in 
addition to VEGF (Xing et al., 2013).  Reciprocal effect was also detected by enhancing 
osteodifferentiation in this model by upregulating the gene expression of ALP, OCN and 
Runx2 (Stahl et al., 2004, Thein-Han and Xu, 2013).  In addition, in vivo studies 
supported the validity of capillary-like structures developed in vitro by using primary 
endothelial and bone cells through anastomosis of these structures with host vasculature 




b. Endothelial cells and mesenchymal stem cells differentiated to osteoblasts 
 
When mesenchymal stem cells are isolated from bone marrow and undergo osteogenic 
differentiation they become human osteoprogenitor cells (HOPs).  HOPs were co-cultured 
instead of primary osteoblasts with primary endothelial cells in order to investigate the 
advantages of this model on angiogenesis and osteogenesis mechanisms (Kaigler et al., 
2003, Guillotin et al., 2008).  Comparable findings were associated with this cellular 
model as capillary-like structures were developed and angiogenic factors were detected 
such as VEGF and Ang-1,2 (Grellier et al., 2009, Pedersen et al., 2012, Li et al., 2013a, 
Li et al., 2011).  Furthermore, applying this co-culture model with 3D scaffolds fabricated 
from β-TCP, HA/β-TCP and silk/HA biomaterials enhanced osteodifferentiation (Kang et 
al., 2013, Kim et al., 2014b, Sun et al., 2012).  Also, supporting in vivo studies displayed 
the functionality of capillary-like structures developed in vitro by anastomosing with host 
blood vessels post implantation (Rivron et al., 2012, McFadden et al., 2013, Ma et al., 
2014). 
 
c. Endothelial progenitor cells and osteoblast cells 
 
Early and late outgrowth endothelial cells (OECs) are endothelial-like cells isolated from 
EPCs.  These cells were the cells of interest as an endothelial cell source in co-culture 
models composed of primary osteoblasts and endothelial progenitors (Fuchs et al., 2007).  
Capillary-like structures were formed by co-cultured OECs and OBs on cell culture 
plastic, starch-poly (caprolactone) and Ca-deficient HA-polylactone scaffolds (Dohle et 
al., 2010, Fuchs et al., 2009, Fuchs et al., 2010b).  Various angiogenic factors were 
upregulated including Ang-1and 2, VEGF and Platelet-derived growth factor subunit B 
(PDGF-BB) (Dohle et al., 2011, Li et al., 2013b).  Also, co-cultured cells promoted 
osteogenic differentiation and calcification in comparison to mono-cultured cells by 




previously mentioned models, anastomosis with blood vessels surrounding implanted 
scaffolds were also confirmed (Fuchs et al., 2009, Ghanaati et al., 2011). 
 
d. Endothelial and osteoblast differentiated cells from progenitor stem cells 
 
Following previous models, OEC and HOPs were considered interesting cell sources in 
bone regeneration studies (Fu et al., 2014).  Promising outcomes were represented in 
capillary-like structures formation in vitro and anastomosis with the host vasculature post 
implantation in vivo (Liu et al., 2012, Shi et al., 2014).  Increased production of VEGF, 
PDGF, Ang-1, 2 and ALP reflected the enhanced angiogenesis and osteogenesis 
processes (Kolbe et al., 2011, Thébaud et al., 2012).   
 
1.9.1.3 Single cell source 
 
Co-culturing cells that originate from the same cell source can take bone regeneration 
one-step closer to clinical application.  In order to investigate this possibility, MSCs were 
differentiated into bone-like and endothelial-like cells and co-cultured in vitro on cell 
culture plastic and on β-TCP for an in vivo study (Tao et al., 2009).  However, only 
osteogenic differentiation was evaluated in vitro in which ALP and OCN productions 
were significantly higher in co-cultured group.  In addition, histological analysis showed 
more bone and vessels formation in implanted scaffold in vivo with co-cultured cells.  
ASCs were also used as a single cell source promoting both osteogenesis and 
angiogenesis synergistically (Shah et al., 2014).  Cells were co-cultured on polylactic 
scaffolds in 1:1 ratio.  Although angiogenesis and osteogenesis were significantly induced 
in endothelial-like cells and osteoblast-like cells monocultures respectively in vivo, there 





More studies are still required to optimise the ratios of cells used in co-culture models and 
long-term studies are also needed to assess the validity of the blood vessels developed.  In 
addition, in order to regenerate critical size defects, the number of cells, the required time 
for cell culturing as well as the necessary amount of differentiating agents are still raising 
questions if this method is clinically suitable in inducing angiogenesis within bone 
scaffolds. 
 
1.9.2 Growth factors, drugs and gene delivery. 
 
Functionalizing scaffolds in order to induce in situ vascularization is of great interest in 
bone engineering.  Incorporating GFs in bone scaffolds can facilitate bone regeneration 
by activating specific cell receptors and induce a ligand-receptor interaction.  For 
example, BCP scaffolds loaded with VEGF and implanted into critical size cranial defects 
in Balb/c mice promoted biomaterial vascularization, osseointegration, and bone 
formation (Wernike et al., 2010).  In addition, co-loading of BMP-2 and VEGF was found 
to enhance both vascularization and bone formation (Patel et al., 2008, Young et al., 
2009, Kempen et al., 2009).  Adding laminin, basement membrane protein, to collagen 
scaffolds promoted vascularization by increasing VEGF uptake (Stamati et al., 2014).  
Using CaP scaffolds as drug delivery systems was also explored by using drugs like 
gentamicin, vancomycin and ibuprofen which enhanced the bone healing process (Verron 
et al., 2010, Bose and Tarafder, 2012).  GFs and drugs can be added to scaffolds by 
absorption when scaffold immersed in GFs and drugs containing solutions for fast 
release.  For controlled and prolonged release, GFs and drugs can be encapsulated within 
scaffold material or integrated by covalent immobilization.  However, controlled release 
is quite important to achieve optimal regeneration.  More organized blood vessels 




VEGF release (Ehrbar et al., 2004).  Combining different GFs to be released in a 
controlled manner would complement their functions temporally and spatially (Jain, 
2005).  
 
Another approach is biological delivery of GFs from seeded cells by genetic modification 
(Krebsbach et al., 2000).  Using gene-delivery technique in providing BMP-9 to a non-
union radius bone defect in mice resulted in bridging the gap and improved bone 
regeneration (Kimelman-Bleich et al., 2011).  To promote angiogenesis, and hence bone 
formation, Keeney et al. explored the delivery of a plasmid encoding vascular endothelial 
growth factor165 (pVEGF165) in a mouse intra-femoral model (Keeney et al., 2010).  They 
found that a collagen/calcium phosphate scaffold can mediate transfection and can 
promote bone formation via the delivery of pVEGF165. 
 
1.10 Peptides in bone engineering 
 
There has been a growing interest in developing biomaterials with improved functionality 
for tissue engineering applications (Bokhari et al., 2005).  The main concept is based on 
mimicking the ECM to organize cells into 3D architecture and induce specific cellular 
response in order to regenerate specific tissue type (Yang et al., 2001).  Peptides 
constructed from synthetic amino acids were used to fabricate biological materials that 
can self-assemble via ionic interactions with physiologic solutions (Zhang et al., 1992, 
Zhang et al., 1993).  Different structures were fabricated by self-assembly peptides 
(SAPs) including synthetic membranes, tubules and fibrillar networks (Zhang, 2003).  
SAPs are attractive candidates in tissue engineering as they are biomimetic and provide 
spatial and temporal regulation (Shastri, 2009).  In addition, mechanical and 
physiochemical properties of SAPs 3D structures can be manipulated and optimized to 




self-assembly of a peptide-amphiphile to induce mineralization (Hartgerink et al., 2001).  
They designed the peptides to be reversibly cross-linked and to direct mineralization of 
HA along the axes of the fibres.  In addition, it has been shown that the same SAP 
scaffold can support regenerating different types of tissues.  For example, RADA 16-I is a 
self-assembly peptide developed by Zhang et al. and available commercially as 
PuraMatrixTM was found to support the neurite growth and differentiation, neural stem 
cell differentiation, brain regeneration, osteoblast differentiation and bone regeneration 
(Zhang et al., 1995, Holmes et al., 2000, Gelain et al., 2006, Ellis-Behnke et al., 2006, 
Bokhari et al., 2005, Misawa et al., 2006).  P11-4 is another SAP that was extensively 
studied and was used to treat bone defects, dental hypersensitivity and dental caries (Firth 
et al., 2006, Kirkham et al., 2007).  It was hypothesized that mineralization was achieved 
through de novo nucleation of HA by attracting calcium via the anionic groups of the 
side-chains of the self-assembly peptide.   However, the lack of specific signalling motifs 
in these scaffolds suggested that the 3D nanostructure played a crucial role in 
regeneration.  Gelain et al. showed that RADA16-I has a comparable ultra-structure to 
extracellular matrix (Matrigel) in the nanofibers structure and porosity (Gelain et al., 
2006).  
 
1.10.1 Designer peptides 
 
SAPs can be functionalized to induce specific cellular interaction by incorporating active 
peptide motifs.  For example, coupling of RADA16-I with 2-unit integrin receptor-
binding site of Arginine-glycine-aspartic acid (RGD) binding sequence PRG and laminin 
cell adhesion motif stimulated fibroblasts proliferation, migration and collagen production 
(Kumada et al., 2010, Kumada and Zhang, 2010).  Specific peptides motifs were designed 




and osteopontin motif DGR (DGRGDSVAYG) (Horii et al., 2007).  It was demonstrated 
that ALP activity and OCN secretion were significantly increased in murine pre-
osteoblast (MC3T3-E1).  Self-assembly peptides are nanofibrous 3D scaffolds that 
resemble ECM architecture and enhance regeneration by promoting cell attachment, 
proliferation and differentiation.  In addition, the ease in coupling the peptides structure 
with bioactive motifs makes self-assembly peptides promising candidate biomaterials for 
tissue regeneration. 
 
1.11 Limitations of current systems 
 
For centuries, bone grafting was the treatment of choice in patients suffering from loss of 
bone tissue.  Different materials are still being tested to provide the optimal bone 
regeneration.  To date, engineering a biomaterial in vitro that can replace missing bone 
and induce osteoinduction, osteoconduction, osteointegration and promote angiogenesis 
in vivo has not yet been achieved.  Because bone structure is complex, advanced 
fabrication techniques are replacing the conventional methods in order to mimic the 
complex structure and facilitate the bone regeneration process.  3D printing techniques 
especially robocasting fabricate precise, consistent and customized scaffolds to each 
defect. 3D printed BCP scaffolds showed promising results in inducing bone regeneration 
in both in vitro and in vivo studies (Ricci et al., 2012).  However, vascularization is the 
key factor in regenerating bone in critical sized defects.  Although various cells were 
studied to prevascularize bone scaffolds prior implantation, their clinical use is still 
debatable.  Also, growth factors gained a significant amount of interest in functionalizing 
scaffolds as they play an important role in differentiating and guiding cells migration.  
However, more research is required to determine the best delivery system for a controlled 
release in order to facilitate bone formation.  The use of SAPs in tissue engineering is 




induce tissue regeneration and drug delivery (Gelain et al., 2010, Miller et al., 2010).  
Moreover, SAPs can modify surface properties of materials and facilitate cell attachment 
and proliferation (Yang et al., 2007, Gelain et al., 2007).  However, further studies are 
required to identify the biochemical and environmental factors that can induce bone graft 
vascularization and the optimal factors that can be used to functionalize bone grafts to 
















1.12 Aims of the Study 
 
This study was designed to develop a bone scaffold that can promote cellular interaction 
at the implanted site in order to enhance vascularization and therefore bone formation.  
3D printed BCP scaffolds that showed promising results in bone regeneration were used 
in this study (Ricci et al., 2012).  Two factors were evaluated as methods of enhancing 
osteogenesis in these scaffolds including: 1) pore geometry and 2) novel SAPs; DAR16-II 
fabricated with a reverse sequence of RAD16-II, a free N-terminus and an amide group at 
the C-terminus.  DAR16-II was investigated as a proactive coating material to BCP 
scaffolds.  
 
These aims were intended to add a smart design and matrix that mimics ECM to the 
surface of CaP scaffolds to augment its osteoinductive properties employed by calcium 
and phosphate ions release during scaffolds resorption. 
1.12.1 Main aim of the study 
 
1. To investigate the effect of pore size and geometry in functionalizing 3D printed 
BCP scaffolds. 
2.  To determine if DAR16-II can be used as a proactive coating matrix for BCP 
scaffolds. 
3. To investigate the biological effect of DAR16-II at the cell level on osteogenesis 
and angiogenesis. 
1.12.2 Specific aims of the study 
 
•  Chapter 2 (in vivo) 
 
1) To evaluate the effect of two different pore-geometries; square and round in the 




2) To assess the biological compatibility of BCP scaffolds and DAR16-II. 
3) To evaluate DAR16-II as a BCP coating in enhancing osteogenesis.  
 
• Chapter 3 (in vitro) 
1) To investigate the effect of DAR16-II coating BCP scaffolds on MSCs 
proliferation and osteogenic differentiation.  
2) To explore the effect of DAR16-II on MSCs (fibroblast-like and mesenspheres) 
differentiation without BCP scaffolds. 
 
• Chapter 4 (in vitro) 
1) To evaluate the DAR16-II effect on endothelial cells proliferation, adhesion and 
activation. 

























































Tissue engineering aims to regenerate damaged tissue by restoring structure and function 
of the lost tissue.  In small bone defect, this can be achieved by using a biocompatible 
scaffold that acts as a template on which the surrounding (endogenous) cells migrate, 
proliferate and differentiate.  In CSD, employment of materials with improved 
characteristics such as osteo-inductivity (i.e. the ability to directly promote stem cell 
differentiation into osteoprogenitor cells) is required.  It has been clearly demonstrated 
that during endochondral ossification, angiogenesis and osteogenesis are coupled via 
specialised endothelial cells acting through Notch signalling (Kusumbe et al., 2014, 
Ramasamy et al., 2014).  Endothelial Notch signalling promotes endothelial cell 
proliferation and vessel growth in bone and is required for endothelial Noggin expression.  
This controls the differentiation of perivascular osteoprogenitor cells thereby controlling 
osteogenesis.  Consequently, the development of a scaffold that is able to provide a bio-
active niche that enhances endothelial cell attachment and differentiation would have the 
potential to promote better angiogenic and osteogenic responses in these large defects.  
 
Bioactive BCP is a biocompatible and partially biodegradable material.  It has been 
previously used in treating various maxillofacial defects (Mercier et al., 1996, Hirano et 
al., 1997, OKII et al., 2001).  BCP is composed of amorphous β-TCP [Ca3 (PO4)2] and 
fine crystalline HA [Ca10(PO4)6(OH)2]) in proportions similar to those of natural bone 
(Greenwald et al., 2001).  The HA biomaterial is semi-permanent and ideally, scaffolds 
should entirely remodel/resorb to allow complete bone regeneration.  Therefore, the BCP 
scaffolds developed in this project were fabricated from 15%HA/85%β-TCP colloidal ink 
that result in 99% β-TCP resorbable scaffolds after processing and firing (Ricci et al., 
2012).  β-TCP is an osteoconductive and resorbable biomaterial that allows osteoclastic 




scaffolds were three-dimensionally fabricated by robocasting (three-dimensional ink 
writing or direct write [DW] technology) (Figure 2.1).  
 
              
Figure 2.1 BCP 3D printing technique.  A) Robocasting apparatus (Dr.James Smay’s 
laboratory, Oklahoma State University (OSU), Aerotech Inc., Pittsburg, PA) connected to a 
computer aided program RoboCAD (Robocad 3.1, 3D Inks, Stillwater, OK) to customize the 
BCP scaffold design and control the printing process.  B) Schematic drawing (adapted from 
Smay et al., 2002) of the robocasting apparatus: colloidal gel-based inks were housed in 
individual syringes mounted on the z-axis motion stage.  A cylindrical nozzle disperses the 
ink onto a moving x-y stage.  The first layer is printed on a platform in the x-y plane, after 
that, the gantry (vertical platform supports equipment) ascends in the z direction above the 






In robocasting, concentrated colloidal ink is extruded from a cylindrical nozzle and builds 
a computer-designed scaffold layer-by-layer.  BCP (15%HA/85%β-TCP) scaffolds 
fabricated by robocasting have shown controlled and reproducible architecture and rapid 
bone healing in CSD in a rabbit trephine model in vivo at 6 and 18 weeks (Ricci et al., 
2012).  They described scaffolds printed in the shape of a continuous lattice with two pore 
sizes: 250x250 µm and 400x400 µm.  The larger pore size, part of the printed scaffold, 
was similar to cancellous bone comprising 70% bone and scaffold while 30% was 
marrow and soft tissue.  After 16 weeks, scaffolds showed 30% remodelling through 
osteoclastic activity with consistent bone growth across the defects (Ricci et al., 2012).  In 
addition to the consistent printing of pores shape, size and strut size (the thickness of the 
printed ink) can also be customized by firing temperature and colloidal particle size. 
Moreover, scaffold struts are nanoporous structures that can allow material adsorption.  
 
BCP scaffolds are highly osteogenic, safe and efficient bone replacement material that 
showed comparable regeneration capacity to autologous bone grafts (Fellah et al., 2008).  
This was demonstrated by comparing osteogenicity of BCP fillers to autografts in ectopic 
and orthotopic sites in adult white milk goats. BCP showed superior stability and 
osteogenic properties compared to autologous bone grafts in CSD defects (Fellah et al., 
2008).  Hence, developing new strategies to induce vascularization in BCP scaffolds can 
improve its regeneration potential and enhance bone formation.  Several strategies have 
been proposed to enhance vascularization including: cell loading, growth factors delivery 
and the design of 3D scaffolds (Crisan et al., 2008, Ferrara et al., 2003, Mannsfeld et al., 
2010).  However, to date, these methods have achieved limited success in increasing 
vascularization in new bone.  On the basis of these facts, we proposed to study the effect 
of the scaffold internal structure including pore size and geometry in enhancing 




2.1.1 Pore geometry 
 
Pore shape has a significant influence on tissue regeneration as demonstrated in various in 
vitro and in vivo studies (Table 2.1).  It has been established that the rate of tissue 
formation is proportional to the surface curvature (Rumpler et al., 2008, Bidan et al., 
2012, Bidan et al., 2013).  Particularly, curvatures in the shape of concavities have been 
shown to enhance tissue growth in comparison to convex or flat surfaces (Ripamonti et 
al., 2012, Bidan et al., 2012, Bidan et al., 2013).  Furthermore, concave surfaces showed a 
higher actin and myosin fibre formation suggesting a higher state of cell stress 
(Gamsjäger et al., 2013).  Moreover, surface concavities of calcium phosphate scaffolds 
enhanced mineralization in vitro (Bianchi et al., 2014).  Sacarano et al. showed that the 
number of blood vessels formed with TCP/HA coated titanium scaffolds in rabbit’s tibia 
were significantly higher in concavities compared to convex surfaces (Scarano et al., 
2014).  Besides mineralization and vascularization, pore geometry was found to influence 
inflammation by producing pro-inflammatory cytokines: tumor necrosis factor (TNF)-α 
and interleukin (IL)-12/23 in vitro with larger and wider angle pores (Almeida et al., 
2014).  It has been established that a moderate level of inflammation is required during 
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2.1.2 Pore size 
 
It was demonstrated that the 400 µm is the ideal pore size for blood vessels formation 
(Bai et al., 2010).  Scaffolds with larger pore size showed no significant difference on 
scaffold vascularization.  
 
Kommareddy et al. studied the kinetics of preosteoblasts MC3T3-E1 tissue growth in 3D 
channels in different polymeric scaffolds.  They demonstrated that growth follows two 
stages (Kommareddy et al., 2010); the first stage is material dependent, cell attachment 
and differentiation is affected by material composition and stiffness.  After a few weeks, 
the second stage of tissue growth becomes dependent on pore geometry rather than 
scaffold material as the cells begin to grow within their own matrix.  A following study 
by Tamjid et al. supported the same findings in which they described tissue growth into 
3D channels and showed that pore geometry was the main factor in the final stage of 
tissue growth within the channels (Tamjid et al., 2013).  However, to date no long in vitro 
or in vivo studies have been reported that assess the effect of pore geometry on bone 
regeneration.  In the present study, two different pore geometries were compared: square 
and round.  The smallest pore size achieved by 3D printing to form round-shaped pores 
was 800 µm, while square pores were printed at 400 µm.  This square pores were used as 
controls in this study as they were previously described and successfully induced bone 
formation across CSDs in rabbit skull (Ricci et al., 2012).   
 
However, the biological process of angiogenesis should be considered in order to induce 
cell adhesion, growth and angiogenesis in the designed scaffold.  Cell adhesion is critical 
for blood vessels formation and integrines, cell adhesion molecules, were found to play 
an essential role during vascular regeneration (Brooks et al., 1994, Eliceiri and Cheresh, 




found to be involved in blood vessels formation (Camenisch et al., 2002).  Type αv 
integrin in particular was highly expressed in activated ECs during wound healing 
(Eliceiri and Cheresh, 1999).  These integrins specifically recognize Arg-Gly-Asp (RGD) 
peptide in ECM to regulate the EC migration and adhesion (Reynolds et al., 2009).  
Hence, the use of a smart matrix that can mimic the RGD peptides in conjunction to BCP 
scaffold can recruit activated EC required for angiogenesis and enhance bone 
regeneration.  In order to develop this matrix, we proposed to use self-assembly peptides 
(SAPs), synthetic peptides, which have a peptide sequence similar to RGD to enhance the 
biological cell response of 3D printed scaffolds.  
 
2.1.3 Self-assembly peptide 
 
SAPs consist of alternating ionic hydrophilic and hydrophobic amino acids.  These 
peptides interact with salt-containing solutions and form hydrogels composed of 99.5–
99.9% water (Hauser and Zhang, 2010).  They form stable beta sheets (β-sheets) and have 
been shown to be useful as nanofiber scaffolds (Gelain et al., 2006, Horii et al., 2007, 
Wang et al., 2008).  SAPs interact through: 1) non-covalent hydrogen bonds along the 
backbones, 2) the arrays of ionic + and charge interactions, 3) alanine hydrophobic 
interactions and van der Waals interactions, and 4) water-mediated hydrogen bond 
formations (Yokoi et al., 2005).  The developed β-sheet has been reported to be stable at 
challenging conditions such as high temperatures, wide pH range and concentrated 
denaturing chemicals as urea and guanidium hydrochloride (Zhang et al., 1994).  The 
nanopores developed within SAPs scaffolds range from 5-200 nanometres (Zhang et al., 
2005, Wang et al., 2008).  It was shown that these nanoporous scaffolds significantly 
facilitated cell infiltration, oxygen and signalling molecules’ delivery, as well as waste 




materials have shown the ability to promote cell attachment, tissue regeneration and to be 
useful in drug delivery (Zhang et al., 2005).  The original SAPs sequence was inspired by 
a yeast protein called Zuotin (Zhang et al., 1992).  Zuotin has a repetitive 16-reside 
sequence motif, n-AEAEAKAKAEAEAKAK-c (EAK16-II), of alternating Lysine-
Alanine-Glutamate segments. Modified SAPs with Arginine–Alanine–Aspartate amino 
acids were developed in the following sequences: RADA16-I (AcN-
RADARADARADARADA-CNH2) and RADA16-II (AcN-RARADADARARADADA-
CNH2) in which arginine and aspartic acid residues substitute lysine and glutamate in 
EAK peptides (Zhang et al., 2005).  This RAD motif is similar to the RGD that is found 
in ECM proteins.  As a result, RADA16-I and RADA16-II nanofiber scaffolds showed 
enhanced neural cells attachment, neurite outgrowth and active synapse formation in rats 
(Holmes et al., 2000).  In addition, RADA16-I was found to be a homeostatic scaffold as 
it stopped bleeding in different tissue types in less than 15 seconds (Ellis-Behnke et al., 
2006).  Furthermore, injecting RADA16-II in mouse myocardium, led to the development 
of a favourable nanofiber microenvironment for vascularization by recruiting endothelial 
progenitor cells that form functional vascular structures (Davis et al., 2005).  Moreover, it 
was demonstrated that RADA16-II scaffolds in vitro promoted human microvascular 
endothelial cell survival and capillary-like network formation in the absence of 
angiogenic factors as well as upregulating angiogenic factor VEGF expression 
(Narmoneva et al., 2005).  The alanines in the SAPs sequence develop overlapping 
hydrophobic interactions in water which is similar to silk fibroin produced by the 
silkworm and to spider silk (Zhang et al., 2005).  Due to this distinctive ability in forming 







The SAPs developed in the present study was DAR16-II (ADADARARADADARAR), 
the reverse sequence of RADA16-II with a free N-terminus (amino group: NH2) and with 
an amide group (CONH2) at the C-terminal.  Since the struts of BCP scaffolds are 
nanoporous and the main composition of the ceramic is β-TCP, DAR16-II has the ability 
to form a hydrogel coating by interacting with the ceramic salts.  Both BCP scaffolds and 
the (RADA) motif used in this study were tested in different studies for immunogenicity, 
mechanical properties, degradation and cellular interactions, both were found 
biocompatible and enhanced cellular interactions in in vitro and in vivo models (Zhang et 
al., 1995, Holmes et al., 2000, Ricci et al., 2012, Witek et al., 2013). 
 
 
In the present study, an in vivo rabbit model was chosen to assess the pore geometry and 
DAR16-II effects on bone regeneration.  Rabbit models are the most commonly used 
animal models in musculoskeletal research (Neyt et al., 1998).  Rabbits have a fast 
skeletal turnover and it was found that their bone mineral density and fracture toughness 
of mid-diaphyseal bone is similar to that of humans (Wang et al., 1998, Castaneda et al., 
2006).  Hence, due to these features, in addition to their availability and ease of housing 
and handling, rabbits are considered the first animal model choice to test bone scaffolds 












Using the rabbit model, the objective of the study was to investigate the osteoinductive 
potential of DAR16-II; a modified self-assembling peptide (developed by Prof/Dettin at 
Padova University) adsorbed into the surface of a 3-dimensional (3D) printed BCP 
scaffold together with pore geometry.  
 
The main aims of the present study were to: 
1. Optimize and to develop a 3D BCP scaffolds (produced in Dr.James Smay’s 
laboratory (Oklahoma State University (OSU)) providing an off-the-shelf 
custom-fabricated bone scaffolds.   
2. Enhance the biological response by supplementing the scaffolds with factors to 
induce vascularization and bone formation, thus taking the 3D BCP scaffolds one 
step closer to the original aim.   
3. Two factors were evaluated as a mode of enhancing osteogenesis in the 3D 
printed scaffolds: 1) pore geometry and 2) self-assembly peptides (SAPs) 













2.2 Materials and Methods 
2.2.1 Scaffold fabrication 
2.2.1.1 Calcination and attrition milling 
 
Commercially available powders of HA (product 10185602, lot 43640; Honeywell, 
Seelze, Germany) [Ca10(PO4)6(OH)2] and β-TCP (product 21218, lot 1305078; Sigma-
Aldrich, St Louis, MO) [Ca3(PO4)2] were calcined in an alumina crucible at 800°C (for 
β-TCP) and 1100°C (for HA) for 11 hours (Figure 2.2).  The powder was attrition milled 
(0.9-1.1 mm zirconia milling media; Union Process, Akron, OH) in ethanol (EtOH, 
analytic purity, product 241000200; Fisher Scientific, Hampton, NH) for 3 hours (model 
L001, Szegvary Attritor System; Union Process).  After that, the suspension was 
separated from milling media and the ethanol-ceramic slurry was centrifuged in an angled 
rotor at 8000 revolutions/min for 4 minutes in polycarbonate centrifuge tubes (Eppendorf 
5804 centrifuge, Eppendorf AG, Hamburg, Germany).  Following centrifugation, the 
ethanol was decanted and the solid deposit was dried in an Oakton low-temperature oven 
at 80°C for 4 to 6 hours.  Next, the solid material was dry milled for 5 minutes on a paint 
shaker with zirconia milling media (10-20 pieces of 10-mm-diameter milling media in a 








Figure 2.2 HA and β-TCP ceramic powders were converted into stable, small particles by 
calcination and attrition milling and then converted into colloidal gel formulations.  Tool 
path calculation was designed with a CAD code for the two pore geometries: square and 
round.  The robocasting direct-write machine executed the code (x, y, z linear interpolation) 
extruding the HA and β -TCP filaments through a fine nozzle (330µm) in the desired pattern 
and dimensions.  The green body ceramic obtained at the end of the robocasting process was 
dried at room temperature and then heated to burn out the polymer binder and sinter the 
ceramic particles to achieve the final scaffold dimensions, strength, and density.  At the end, 
scaffolds were either coated with DAR16-II or used as controls without coating. 
 
2.2.1.2 Ink formation 
 
The calcined and milled ceramic powder was used for the ink formulation. Concentrated 
HA and β-TCP suspensions, where volume fraction of ceramic φceramic = 0.45 to 0.5, 
were produced by mixing an appropriate amount of ceramic powder and ammonium 
polyacrylate (Darvan 821A; RT Vanderbilt, Norwalk, CT) solution to disperse particles 
into water (Table 2.2).  The optimal dispersant proportion per gram of ceramics was 14.5 
mg as determined by trial and error.  The qualitative metric was determined so that the 
suspension would become very fluid after a short (60 seconds) mixing period upon 
addition of the powder to the dispersant solution.  The powders were added to the mixture 
in 2 parts: first β-TCP and then HA according to the calculated weight, maintaining the 
85:15 ratio.  After each addition of powder, the suspension was mixed in the conditioning 
mixer (Thinky AR-250; Thinky, Tokyo, Japan) for 3 minutes after the addition of β-TCP, 




methylcellulose (Methocel F4M, Dow Chemical Company, Midland, MI) 5% weight 
aqueous solution, was added as a thickening agent and was mixed for 1 minute, and de-
foamed for 30 seconds the conditioning mixer.  As a final step, the suspension was gelled 
by adding poly-ethyleneimine (PEI, Product 195444, INC Biomedicals Inc, Aurora, OH) 
10% weight solution, and mixed and de-foamed for 1 min and 30 seconds respectively.  
This resulted in the final ink that was used for printing.  The ink needed to be stiff enough 
to maintain the shape after deposition but also needed to be able to flow through the 
syringe nozzle easily when a minimum amount of pressure was applied.  The desired 
consistency was achieved by adding further PEI drop by drop and mixed and de-foamed 
after each drop was added. 
 
Material Quantity in grams 
DI water 17.89 
Darvan 821A 1.02 
β-TCP 54.55 
HA 9.44 
F4M (5%) 3.89 
Polyethyleneimine (10%) 1.10 
Total Volume= 45mL 
Liquid Volume= 24.30mL 
Solid Volume= 20.70mL 
Density of β-TCP= 3.1 g/cm3 
Density of HA= 3.04 g/cm3 
 
 
Table 2.2 φ ceramic = 0.46 HA: β-TCP = 15:85 Ink Formulation. 
 
 
2.2.1.3 Scaffolds robocasting  
 
Robocasting uses a gantry robotic control (Aerotech Inc., Pittsburg, PA) to extrude 




controlled.  The ink syringe containing the colloidal ink is attached to a z-axis mounted 
controlled stage for printing on a moving x-y stage.  The 3-axis motion is independently 
controlled by a custom-designed, computer aided program RoboCAD (Robocad 3.1, 3D 
Inks, Stillwater, OK).  Square-shaped scaffolds (10x10-mm, 3-mm thickness with 
400µm-square or 800µm-round pores) were designed on the CAD program (Fig 2.3).  
  
             
 
Figure 2.3 The CAD design developed by RoboCAD 3.1 software for the BCP scaffolds.  
Two patterns were designed: square and round pores with 400 µm and 800 µm pore size 
respectively.  The designs were saved as “dot g” files and once the design was ready, a 
syringe was filled with the colloidal ink and loaded onto the robocasting apparatus and a 
ceramic printing surface was placed below the syringe in the oil medium to ensure a levelled 
surface for printing. 
 
The CAD design was transferred to machine code to drive the x-y plane robotic 
deposition of the ink contained in a syringe.  The round shaped pores could not be printed 
in a size smaller than 800 µm as the ink collapsed with the cylindrical nozzle used.  Once 
a layer was printed, the nozzle was translated up (Δz) in the z-axis and another layer was 




function of the deposition nozzle diameter (D) and for all structures fabricated in this 
project, a Δz of 0.79D was used.  The ink was housed in a syringe of 150-500 µm internal 
diameters (EFD Inc, Nordson, Ohio) and deposited through a cylindrical nozzle of 330µm 
internal diameter to produce the required scaffolds.  After sintering the diameter of bone 
struts was designed to be 250µm.  The ink exits the nozzle as a continuous, rod- like 
filament.  The layers were printed at 6 to 10 µm/s deposition velocity in low viscosity 
paraffin oil (Ultra-Pure lamp oil, Lamplight Farms Inc., Menomonee Falls, WI).  An 
alumina ceramic plate was used as the substrate (on which the scaffolds are printed) in the 
oil medium. This oil bath was used to prevent drying of printed scaffolds and to allow 
fine features to be patterned without clogging the nozzle. 
 
2.2.1.4 Heat Treating the Scaffolds 
 
Heat treatment was carried out for scaffold material to sinter and to enhance mechanical 
strength.  It is a slow process that takes almost 7 hours with a gradual increase in 
temperature.  The firing schedule started by heating at 4°C/min until 400°C, a hold at 
400°C for 1 hour, then heated rapidly by 5°C/min until 1100°C and a hold of 4 hours and 
finally cooled by 9°C/ min until the samples reach room temperature and the desired 
scaffolds were achieved (Figure 2.4). 
         
Figure 2.4 BCP scaffolds with square and round pore geometries after sintering.  10x10 mm 




2.2.2 Peptide synthesis 
2.2.2.1 Materials 
 
The solid support resins Rink-Amide 4-Methylbenzhydrylamine hydrochloride (MBHA) 
and the Fluorenylmethyloxycarbonyl (Fmoc) protected amino acids were from 
Novabiochem (Merck KGaA, Darmstadt, Germany).  The coupling reagents 2-(1H-
Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and 1-
Hydroxybenzotriazole (HOBt) were from Advanced Biotech (Seveso, MI, Italy). N,N-
diisopropylethylamine (DIEA) and piperidine were from Biosolve (Leenderweg, 
Valkenswaard, Netherlands).  Triethoxysilane (TES) was from Sigma-Aldrich 
(Steinheim, Germany).  Solvents including N,N-dimethylformamide (DMF), 
trifluoroacetic acid (TFA), N-methyl-2-pyrrolidone (NMP) and dichloromethane (DCM) 
were from Biosolve. 
 
 
2.2.2.2 SAPs fabrication 
 
The peptide was synthesized on Rink-Amide MBHA resin (0.59 mmol/g) with Fmoc 
chemistry using a synthesizer Model 431 A (Applied Biosystem, Forster City, CA, USA) 
with 0.25 mmol scale.  The following side-chain protections were used: tert-butyl ester 
(OtBu) for Asp; 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) for Arg.  The loading of 
the first amino acid was performed with a double coupling.  The following four insertions 
were carried out with single couplings (4 equivalents of Fmoc-amino acid, 4 eq. HBTU, 4 
eq. HOBt, 8 eq. DIEA, for 25 min) and the remaining with double couplings.  The 
coupling solvent was NMP.  Fmoc removal was carried out with 20% piperidine in NMP 
for 3 min.  The peptide was unblocked from the resin and unprotected from side chain 
protecting groups using 95% TFA, 2.5% TES, 2.5% water mixture (v:v:v), for 2 h and 30 




performed through reverse phase high performance liquid chromatography (RP-HPLC).  
The homogeneity (>98%) of the purified product was obtained by integration of the 
analytical HPLC peaks, whereas the identity of each product was determined by 
electrospray ionization time of flight (ESI-TOF) mass spectrometry (exp. mass = 1670.9 
Da; theor. mass = 1670.8 Da).  SAPs were synthesized as C-terminal amides with the 
following sequence: ADADARARADADARAR, named DAR16-II.   
2.2.2.3 DAR16-II solution 
 
The solution was prepared in 0.15% w/w concentration in distilled water.  300µl was 
required for each BCP scaffold. 22.5 mg of DAR16-II was dissolved in 15 ml distilled 
water.  Solution was sterilized by filtration with 0.22 um filters (diameter 4 mm, Millex 
Cod. Z227501 by Millipore).  Unused solution can be stored in -20°C.  
2.2.3 In-vivo study 
2.2.3.1 Bone substitute scaffolds 
 
The BCP scaffolds were divided into the following groups (Table 2.3): 
 
Group Pore shape Pore size DAR16-II 
1 Round 800 µm – 
2 Round 800 µm + 
3 Square 400 µm – 
4 Square 400 µm + 
 
Table 2.3 The four groups of BCP scaffolds that were implanted in calvaria rabbit model to 




The study was performed in collaboration with the Faculty of Medicine, University of 
Niš, Serbia, with the approval of the Local Ethical Committee (ref.–no.: 01–9337-25).  
The animals were previously obtained from the Military Medical Academy (Belgrade, 




implantation the animals were maintained for one week to allow for acclimatization, 
under standard conditions with regular animal pellets, access to water ad libitum and an 
artificial light–dark cycle of 12 h each. 
 
2.2.3.3 Experimental design and implantation 
 
The rabbits were randomly distributed into the study groups as shown in table 2.4.  In 
each rabbit, three defects were made in which two were filled with BCP scaffolds and one 
was left empty as a control.  The animals were anesthetized by an intraperitoneal injection 
of ketamine hydrochloride (10mg/kg) potentiated with infiltrative local anaesthesia of 
operation site with 1.6 ml Xylocaine Xilazine [2%] and the implantation region was 
shaved and disinfected with iodine solution.  Subsequently, the calvaria was exposed by 
medio-sagital skin incision approaching bone, lateral mobilisation reflection of the skin, 
galea and periosteum.  Three critical size bone defects (10 mm in diameter) were 
performed in each animal (one central defect in the midline of frontal squama of frontale 
and one defect in each parietal bone: two defects in both sides of parietal bone) (Figure 
2.5) (SkyScan 1272 µ X-ray CT imager, Bruker, Germany).  Drilling was made using 
round diamond burs under water irrigation avoiding dura mater lesion.  To coat BCP 
scaffolds with DAR16-II; each scaffold was immersed in 300µl DAR16-II solution for 1 







Table 2.4 Showing the experimental design and the animal distribution over the BCP 
scaffolds used to fill prepared defects.  
 
After placement of BCP scaffolds into the two parietal bones defects, the incision was 
sutured in layers using interrupted stiches of resorbable polyglycolic-acid (PGA) 5/0 for 
periosteum and running polypropylene 4/0 stitch for peri-cranium and skin closure.  
 
 
Figure 2.5 CT scans show the rabbit calvaria defects and BCP scaffolds implanted.  Three 
defects were prepared (10x10 mm) in which two parietal defects were filled with BCP 
scaffolds (with and without DAR16-II coating) and one frontal defect was used as a control 
defect without biomaterial insertion.  After 8 weeks, experiment was terminated and defects 
were analysed.    
 
 
2.2.3.4 Processing procedure  
 
At 8 weeks postoperatively, the rabbits were euthanized by one overdose of the ketamine 
and the calvarial bones were harvested for radiographic and histological examination.  











Fresh calvarial specimens were cut ensuring 0.5 cm bone was present around the implant 
and control.  Immediately after the euthanasia, the implanted bone substitute scaffolds 
were cut out together with the peri-implant tissue surgical scissor.  Following excision, 
the explants were fixed in 10% neutral-buffered formalin for 48 hours and decalcified in 
10% ethylene-diamine-tetraacetic (EDTA) acid (Fluka, Germany) at room temperature 
for 7-10 days.  Histological preparation was performed at the FORM-Lab of the Clinic of 
Oro-Maxillofacial and Plastic Surgery of the Goethe University Frankfurt.  Specimens 
were dehydrated in a series of increasing alcohol concentrations followed by Xylol 
treatment and embedding in paraffin.  Then sections with a thickness of 3-5 µm were 
made using a rotation microtome (Leica RM2255, Wetzlar, Germany).  Slides were 
stained using the following histochemical staining: Haematoxylin and Eosin (H&E), and 
Azan as previously described (Ghanaati et al., 2010). 
 
2.2.3.5 Histology analysis 
 
Histological analysis was performed using a Zeiss light microscope (Zeiss PrimoStar HD, 
Carl Zeiss Microscopy GmbH, Jena, Germany).  Histological images were photographed 
using a microscopic camera integrated into the above-mentioned microscope connected to 
a computer running the ZEN 2 lite software (Carl Zeiss Microscopy GmbH, Jena, 
Germany). 
 
2.2.3.6 Histomorphometrical measurements 
 
Histo-morphometrical analysis was performed following established protocol quantifying 
the different tissue fractions within the implantation beds of bone substitutes and, thus, 
the comparison of the bone regeneration mediated by different materials (Ghanaati et al., 




100x orginal magnification (OM) were acquired by a light microscope (Nikon® Eclipse 
80i, Tokyo, Japan) equipped with an automatic scanning table (Prior, USA), a digital DS-
Fi1 camera and a Digital sight DS-L2 unit (both: Nikon, Tokyo, Japan) connected to a 
computer running the NIS-Elements software version 4.0 (Nikon, Tokyo, Japan) and used 
for histomorphometrical analysis.  The histomorphometrical analysis was performed with 
the scientific image-analysis program ImageJ (Schneider et al., 2012).  After 
measurement of the total area of the implants, the areas of new-built bone tissue, of the 
remaining bone substitute scaffolds and of connective tissue within the implantation beds 
were measured on four slides from different animals per group.  Based on this data the 
percent area of the three tissue fractions was determined and statistically analysed. 
2.2.3.7 Statistical analyses  
 
Results are expressed as mean ± standard deviation (SD).  Data were analysed using 
GraphPad Prism 6.0c software (GraphPad Software Inc., La Jolla, USA) statistical 
software.  Significance was predetermined at α = 0.05.  One-way analysis of variance 
(ANOVA) with post hoc Tukey's Multiple Comparison Test was used to compare the 
means among groups.  
 
2.3 Results  
2.3.1 Results of the histological analysis 
 
The histological analysis showed bone growth along the braces of all four-bone substitute 
scaffolds (Figure 2.6 A–D).  Bone growth of a uniform pattern was observed along the 
material surfaces coated with DAR16-II up to the centres compared to non-coated 
scaffolds.  Square/small pore scaffolds coated with DAR16-II showed more newly 





In the control group, growth of new bone outgoing from the defect borders was visible 
which did not extend to the defect centres (Figure 2.6 E).  In the central defect region, a 
membrane-like structure composed of a fibre-rich connective tissue was found that 
seemed to bridge the open spaces that were not covered by newly formed bone (Figure 
2.6 E). 
 
Furthermore, the histological analysis revealed that most of the surface areas of all 
scaffolds were covered by newly formed bone (Figure 2.6 A1–D1).  Within the 
neighbouring connective tissue, moderate numbers of inflammatory cells, i.e., mostly 
macrophages and some lymphocytes and fibroblasts, were observed together with 
moderate numbers of blood vessels (Figure 2.7).  At the material surfaces of all four-bone 
substitute scaffolds that were not covered by bone tissue, mononuclear cells of the 
macrophage line were detectable beside a few biomaterial-associated multinucleated giant 

















Figure 2.6 Overviews over the implantation areas of the four BCP bone substitute scaffolds 
(A: round (800µm), B:  round (800µm) + DAR16-II, C: square (400µm); D: square (400µm) 
+ DAR16-II) and the defect area of the control group (E).  (A-D) In case of the four different 
bone substitute scaffolds (BS, black arrows) new-built bone (black asterisks) along the 
material surfaces up to the centres of the implantation sides was found (CT= connective 
tissue).  (E) In case of the control defects (blue arrow) without material insertion bone 
growth (blue asterisks) outgoing from the defect borders towards the centre was observed.  
In the central defect area a membrane-like structure (yellow asterisks) composed of a fibre-
rich connective tissue was found that appeared to cover the underlying brain tissue (NBT = 
neighbouring bone tissue, CT = connective tissue) (Hematoxylin and eosin (H&E) staining, 




   
Figure 2.7 Integration and cellular response of the four BCP bone substitute scaffolds (A1 
and A2: round (800µm), B1 and B2: round (800µm) + DAR16-II, C1 and C2: square 
(400µm); D1 and D2: square (400µm) + DAR16-II).  A1 – D4 show that the surfaces of all 
bone substitute scaffolds (BS) were mainly covered by new-built bone tissue (NB).  The 
surrounding connective tissue (CT) contained only low amounts of inflammatory cells and 
moderate vessel numbers (red arrows) (Azan-staining, 100x magnification, scale bars = 100 
µm).  A2 – D2 show the tissue reactions to the bone substitute scaffolds (BS) at the material-
tissue interfaces. Mainly mononuclear cells (black arrows) were found at the surface areas 
that were not covered by new-built bone tissue (NB).  Only low numbers of biomaterial-
associated multinucleated giant cells (BMGCs, arrowhead in A2) were detected involved in 
the tissue reactions to all four scaffolds (BS) (CT = connective tissue, read arrows = vessels) 




2.3.2 Results of total bone and histomorphometric analyses 
 
Total bone analysis (Figure.2.8) showed that more bone was formed with DAR16-II 
coating in both pore geometries.  Also, more bone was formed in the presence of square 
pores compared to round pore geometry.  The histomorphometric analysis showed that 
the amount of bone in both pores; round and square pores was higher in the presence 
DAR16-II (Figure 2.9).  In scaffolds with square pores, the amount of newly formed bone 
was significantly higher with the DAR16-II coating compared to non-coated square pores 
scaffold (* p ≤ 0.05) (Figure 2.9).   
 
 
                       
                               
Figure 2.8 Total-bone developed in the four BCP scaffolds normalized by the lesion area.  
Scaffolds with round and square pore geometry induced more bone formation when coated 
with DAR16-II.  More total-bone was found in square pore scaffolds compared to round 




                      
Figure 2.9 Newly formed bone in contact with the four BCP bone substitute scaffolds; 
(round pores with and without DAR16-II coating, square pores with and without DAR16-II 
coating).  More bone in contact was detected with DAR16-II coating in both pore 
geometries.  Coated scaffolds with round pores showed the highest amount of bone in 
contact development.  Coated scaffolds with square pores showed a significant difference in 
forming bone in contact compared to non-coated square pore scaffolds (p<0.05).  Data 















 2.4 Discussion 
 
It is well established that angiogenesis and osteogenesis are coupled during bone 
formation and remodelling (Ramasamy et al., 2014, Kusumbe et al., 2014, Lafage-Proust 
et al., 2015).  Consequently, bone scaffolds should acquire particular characteristics in 
order to induce vascularization to initiate and maintain new bone formation. Successful 
bone regeneration is dependent on scaffold chemical composition, continuous porosity, 
surface topography and 3D structural design (Zadpoor, 2015).  It has been shown that 
pore size has a direct effect on bone regeneration and neo-tissue formation; however the 
optimal pore size remains debatable.  For example, it was claimed that the optimal pore 
size for bone ingrowth was 100-400 µm (Itälä et al., 2001).  Kuboki et al. precisely 
showed that HA scaffolds with pore size ranges from 300-400 µm were optimal for bone 
formation by showing higher ALP, OCN content and bone ingrowth (Kuboki et al., 
2001).  However, recently Taniguchi et al. have demonstrated that titanium scaffolds 
implanted in rabbit tibia significantly induced bone ingrowth with 600µm and 900µm 
pore sizes compared to 300 µm (Taniguchi et al., 2016).  In contrast, work by Bai et al. 
showed that pore size of 400µm was found to be the upper limit for vascularization with 
no significant difference observed with larger pore size (Bai et al., 2010).  Hence, in the 
in vivo study described in this chapter, 400 µm was the smallest pore size used in order to 
ensure adequate vascularization.   
 
The pioneering work of Rumpler et al. in pore geometry established the theory of 
curvature-driven growth in which tissue formation follows the pore curvature (Table 2.1) 
(Rumpler et al., 2008).  It was reported that tissue growth increased as the pore curvature 
increased.  However, as the tissue filling the porous channels reached a circular geometry, 
this effect disappeared and growth followed a linear progression over the different pore 




bone growth by applying the shape of osteons and hemi-osteons in HA plates (Table 2.1) 
(Bidan et al., 2012).  They proposed a “cord” model in which circular pores resulted in 
more tissue growth compared to semi-circular pores.  Circular pores were filled in a 
concentric way while semi-circular channels were filled layer by layer until the curvature 
surface was flat.  It was demonstrated that cells anchored on curved surfaces, creating an 
actin ‘‘chord’’ by generating tension between the adhesion sites (Bidan et al., 2012).  In 
their study, HA plates with a circular or semi-circular pore were used to assess the effect 
of pore geometry on tissue growth.  In our study, the same concept was applied in 
designing scaffold pores (Figure 2.3).  However, in our study, the optimized BCP 
colloidal ink used in printing scaffolds in low viscosity paraffin oil was only able to 
fabricate scaffolds with 800µm round pores as the smallest pore size achieved without 
pore closure during printing. On the other hand, square-pore scaffolds were printed with 
square 400µm pores as a control.  Despite pore size differences, histomorphometric 
analysis showed that there was no significant difference between round and square pores 
in total bone and bone in contact (Figure 2.8, 2.9).  In contrast, round pores with DAR16-
II coating showed the highest and most consistent bone in contact formation compared to 
other groups (Figure 2.9).  Furthermore, DAR16-II coating enhanced total bone formation 
and bone in contact in both pore geometries (Figure 2.8, 2.9).  This finding demonstrates 
that DAR16-II coating was successful in functionalizing 3D printed BCP scaffolds.  In 
addition, newly formed bone in coated scaffolds (Figure 2.6 B and D) was uniform 
around the pore surfaces all the way to the centre of the defect compared to non-coated 
scaffolds (Figure 2.6 A and C).   
 
The main objective of this study was to functionalize 3D printed BCP scaffolds to 
enhance vascularization and bone formation using a practical and reproducible method.  It 




implantation was able to functionalize scaffolds and induce further bone formation 
compared to non-coated scaffolds.  Moreover, no foreign body reaction was detected and 
a favourable healing environment was demonstrated by the presence of blood vessels 
surrounding the four scaffolds (Figure 2.7).  This agrees with previous studies 
demonstrating that (RADA) motif (the building block of the DAR16-II), is biologically 
compatible (Zhang et al., 1995, Holmes et al., 2000, Narmoneva et al., 2004).  Although 
the reverse sequence; RADA16-II was found to promote vascularization in in vivo and in 
vitro studies, the mode of action was not identified at the cellular and molecular level 
(Davis et al., 2005, Narmoneva et al., 2005).  Our results indicated that DAR16-II 
promoted better bone neo-formation around implanted biomaterials.  This led us to 


















2.5 Conclusion  
 
Our results demonstrated that DAR16-II coating enhances bone formation without 
causing any adverse inflammatory reactions.  In addition, pore geometries had no effect 
on bone formation. Overall, our results demonstrated a clear osteogenic effect of DAR16-
II, which augments the osteoconductive properties of BCP.  Therefore, in the following 
parts of this study we sought to define the cellular and molecular components mediating 













































Bone has an inherent tendency to regenerate following traumatic injury.  Residential stem 
cells, circulating blood cells, proinflammatory and anti-inflammatory macrophages 
orchestrate in order to regenerate the damaged tissue (Raggatt et al., 2014, Das et al., 
2013, Kuroda et al., 2014).  During healing, undifferentiated MSCs are recruited via 
signalling molecules to proliferate and differentiate into chondrocytes and osteoblasts to 
initiate the repairing process (Planell et al., 2009).  
 
3.1.1 MSC-BCP in bone engineering 
 
MSCs have been used with biomaterials for osteogenic studies since the first attempt of 
combining bone marrow-derived MSCs with ceramic scaffolds in an ectopic implantation 
in immune-deficient mice resulted in successful bone formation (Haynesworth et al., 
1992).  Mankani et al. showed that specifically BCP scaffolds and MSC combination was 
successful in regenerating critical-size dogs calvarial defects in a long-term study 
(Mankani et al., 2006a).  The same findings were demonstrated by the same group in a 
similar long-term study using MSCs-BCP combination in regenerating calvarial and 
mandible defects in mouse model (Mankani et al., 2006b). 
 
In humans, MSC-BCP was used as a bone graft in patients with unstable dorsal and 
lumbar spinal injuries (Bansal et al., 2009).  MSC-BCP grafts were implanted on one side 
of the spine and on the other side autologous iliac crest bone grafts were implanted.  Graft 
incorporation and fusion occurred in all patients on the MSC-BCP graft side showing 
analogous healing properties to autografts.  In addition, HA, TCP or their combination 
have been employed in various human clinical studies, to treat long bone defects, 




successful bone formation and good clinical recovery (Quarto et al., 2001, Shayesteh et 
al., 2008, Krečič Stres et al., 2007, Mesimäki et al., 2009).   In order to decide the optimal 
HA:TCP ratio, Arinzeh et al. loaded implants of different ratios of HA and TCP with 
MSCs and implanted them subcutaneously in the back of severe combined immune-
deficient (SCID) mice (Arinzeh et al., 2005).  It was found that 20:80 HA:TCP showed 
the best bone formation iv vitro and in vivo.  The release of calcium and phosphate ions as 
a result of BCP degradation can induce osteogenic differentiation through mechanisms 
that involve extracellular signal-regulated kinase 1/2 (ERK1/2) and cAMP response 
element-binding protein (CREB) signalling pathways in stem cells (Figure 3.1).  
Ca2+ ions infiltrate the cell membrane through ion channels and activate 
calcium/calmodulin (CaM) mediated calcium/calmodulin-dependent protein kinase 
(CaMK2α) (CaMK2α/CAM) pathway (Jung et al., 2010).  CaMK2α/CAM pathway 
activates CREB-CRE (CRE is the cAMP response element) and ERK1/2 pathways 
(Zayzafoon et al., 2005).  These pathways result in signal transduction of CRE and c-FOS 
(a proto-oncogene) pathways and promote osteogenic differentiation via production of 
BMP-2, osteopontin (OPN) and BSP.  In addition, Ca2+ ions can activate the protein 
kinase C (PKC) pathway which modulate osteoblastic differentiation via ERK1/2 
pathway (Barradas et al., 2012).  Inorganic phosphate (Pi) ions also play a pivotal role in 
inducing osteogenesis by activating PKC and ERK1/2 pathways (Beck and Knecht, 
2003).  However, Ca2+ ions are required for phosphate in order to activate the ERK1/2 
pathway via the formation of a calcium phosphate precipitate (CaPp) outside the cell 




             
 
Figure 3.1 Diagram describes the role of calcium ions (Ca2+) and phosphate (Pi) ions in 
osteoblastic differentiation.  Ca2+ and Pi activates two pathways: extracellular signal-
regulated kinase 1/2 (ERK1/2) and cAMP response element-binding protein (CREB).  This 
activates the signal transduction of CRE and c-FOS pathways and promotes osteogenic 
differentiation via BMP-2, OPN and BSP production.  This diagram demonstrates the 
collection findings of Jung et al., 2010, Zayzafoon et al., 2005, Barradas et al., 2012, Beck 
and Knecht., 2003 and Khoshniat el al., 2011. 
 
 
As the MSC-BCP model is well established in osteogenic studies, it was used in the 
present study to investigate the mechanism of DAR16-II coating in direct osteogenesis in 
vitro. 
 
3.1.2 MSCs for in vitro studies 
 
MSCs are defined as “long-term self-renewing cell capable of generating the different 
mesenchymal lineages (osteolineage cells, chondrocytes, adipocytes, and muscle cells)” 




adherence and proliferation capacity up to 50 passages before reaching senescence 
(Hayflick and Moorhead, 1961).  As fibroblasts are abundant in bone marrow stroma, 
confusion in the properties or phenotype can lead to impure MSC isolation (Méndez 
Ferrer et al., 2015).  Human bone marrow MSC derived from CD45− CD71− CD31− 
CD105+ CD146+ nestin+ cell population was able to self-renew and spontaneously 
differentiate into mesenchymal lineage both in vitro and in vivo with potent 
hematopoiesis-supporting capacity (Isern et al., 2013).  These cells were cultured as 
clonal mesenchymal spheres (mesenspheres) and it has been shown that they have the 
highest purity reported by expressing low-affinity nerve growth factor receptor CD271 in 
the absence of CD140a (PDGFRα) expression (Li et al., 2014).  These mesenspheres 
were used in part of this study due to their promising applications in biomaterials 
research. 
 
The objective of the following study was to explore the osteogenic effect of DAR16-II 
coating by seeding MSCs on coated and non-coated 3D printed BCP scaffolds in vitro 
without osteogenic conditioned media in a long-term study.  In addition, the distinct 
osteogenic effect of DAR16-II was investigated by seeding MSCs on coated and non-
coated tissue culture plates in short term-study.  
 
Aims of the study: 
1. Determine if DAR16-II coating of 3D printed BCP can enhance osteogenic 
differentiation compared to non-coated BCP scaffolds.  
2. Explore the effect of DAR16-II on MSCs (fibroblast-like and mesenspheres) 






3.2 Materials and methods 
3.2.1 Cell culturing  
 
Primary human MSCs isolated from bone marrow were obtained from Lonza (Slough, 
U.K.).  The cells were cultured in humidified atmosphere (37 ºC, 5% Carbon dioxide, 
CO2) in standard growth medium consisting of minimal essential medium (MEM), 
penicillin (50 U/ml), streptomycin (50 mg/ml), 20% fetal bovine serum (FBS) (all from 
Sigma-Aldrich, Dorset, U.K.), 10 ng/ml of basic fibroblast growth factor (b-FGF) 
(Prepotech, London, U.K.) and Glutamax (2 mM) (Invitrogen, Paisley, U.K.).  Cells of 
passage 3 were used in this study.  
 
3.2.1 BCP scaffolds coating and cell seeding 
 
BCP scaffolds with square-shaped pores (previously described in chapter 2) were 
immersed in DAR16-II (previously described in chapter 2) solution (0.15% w/w DAR16-
II in water) for one hour at 37°C-5%CO2 atmosphere. Scaffolds without DAR16-II 
coating were used as controls.  MSCs were micro-seeded at a density of 2x105 cells per 
scaffold.  These were micro-seeded in a total volume of 200 µl.  100 µl was micro-seeded 
onto the top of one side of BCP scaffold and allowed to attach for 30 min at 37°C.  The 
scaffold was then turned and the same number of cells was seeded on the other side and 
left undisturbed for a further 30 min for the cells to attach at 37°C-5%CO2 atmosphere.  
Scaffolds containing cells were then flooded with growth medium.  The scaffolds were 







3.2.2 Alkaline phosphatase (ALP) assay 
 
Cell differentiation of the osteoblastic phenotype was determined by measuring the  
ALP production of MSCs.  For lysates preparation, BCP scaffolds from days 14 and 42 
were transferred to 1 ml of sterile water and went through three cycles of freezing, 
thawing at -80°C and 37°C, respectively for 20 minutes.  A standard curve was prepared 
from 200 µg/ml 4-nitrophenol stock solution to give a range from 0 to 100 µg/ml.  50 µl 
of cell lysate was transferred to a 96 well plate and 50 µl of substrate reagent (p-
nitrophenol phosphate, magnesium chloride hexahydrate and triton X-100 in Glycine) 
was added.  The plate was placed on a shaker for 2 minutes and incubated at 37ºC for 20 
minutes and measured spectrophotometrically (Dynex Technologies reader, USA) at a 
test wavelength of 405 nm.  Tests were run on nine samples.   
 
3.2.3 DNA assay 
 
Cell growth and turnover was assessed by measuring total Deoxyribonucleic acid (DNA) 
production using the Hoechst 33258 dye.  100 µl aliquots from the previously prepared 
lysates were transferred to a 96-well plate; 100 µl Hoechst 33258 (Sigma-Aldrich, Dorset, 
U.K.) fluorimetric dye was added to each well.  Hoechst 33258 reacted with lysates and 
DNA standards concentrations were 0, 0.31, 0.62, 1.25, 2.5, 5, 10 and 20 ng/ml.  
Florescence was measured at an excitation of 355 nm and emission wavelength of 450 nm 
on a Fluorometric plate reader (ChameleonTM, Hidex, Finland).  The DNA content was 







3.2.4 Runx2 release  
 
Runx2 is an early marker of osteogenic differentiation.  Supernatants were collected at 
days 14 and 42 and used to measure the amount of release of RUNX2 from cells.  Runx2 
release was measured using Cloude-clone ELISA kit (USCN, China).  Optical density 
was measured spectrophotometrically at a wavelength of 450nm ± 10nm using a DYNEX 
Opsys technologies reader (Dynex Technologies reader, USA). 
 
3.2.5 Gelatine preparation  
 
Gelatine from porcine skin, Type A was dissolved in PBS (all form Sigma-Aldrich, 
Dorset, U.K) in 0.5% concentration.  The solution was autoclaved at 123°C for 28 min 
using a compact 40 bench autoclave (Prioclave, Tactrol 2, RSC/E, UK).  Sterile gelatine 
solution was stored at 4°C. 
 
3.2.6 Seeding MSCs on tissue culture plates for gene expression analysis 
 
6-well plates were either coated with 0.5% gelatine solution (as controls wells) or with 
1:1 15%DAR16-II: 5% Gelatine solution (test wells).  MSCs were seeded at a density of 
3x105 cells in growth medium for 48 hrs.  








3.2.7 Gene expression analysis with quantitative real-time reverse transcription–
polymerase chain reaction (qPCR) 
 
RNA extraction.  Seeded cells were lysed using 300 µl of TRI-reagent (Ambion® 
AM9738).  Each sample was transferred to an eppendorf tube and 60µl of chloroform 
(Sigma-Aldrich, Dorset, U.K) was added and tubes vortexed for 15 sec and then 
centrifuged at 20,000 g for 15 min at 4ºC.  The colourless layer (aqueous phase) on the 
top was transferred into a new tube and the same process was repeated twice.  After that, 
150 µl isopropanol (Sigma-Aldrich, Dorset, U.K) was added.  This was placed at −20°C 
overnight to maximize the yield of RNA before being centrifuged at 20,000 g for 20 min 
at 4°C to give a pellet.  Sample supernatants were removed and pellets were washed twice 
in 1 ml of 75% ethanol by vortexing and centrifuging at 7,500 g for 5 min at 4ºC.  Pellets 
were air-dried and re-suspended in 20 µl of nuclease-free water (Life technologies, 
Paisley, UK).  The RNA yields were determined by spectrophotometry using the 
Nanodrop1000 (ND-1000 spectrophotometer; Isogen Life Science, Ijsselstein, The 
Netherlands). 
 
Complimentary DNA (cDNA) synthesis.  Reverse transcription was performed using 500 
ng of total RNA sample, which was mixed with 2 µl of RT buffer (500 mM KCL, 100 
Mm Tris-HCI, Ph 8.3).  0.8µl of 25xdNTP mixture, 2µl of 10x random hexamers, 0.4µl 
of RNase inhibitor (20U/ml) and 1µl of MultiScribe Reverse Transcriptase (50U/µl) (all 
from high capacity cDNA reverse transcription kit, Applied Biosystems, Warrington, 
UK).  Nuclease-free water was added to bring the final reaction volume to 20µl.  The 
mixes in the tubes were then incubated at 25ºC for 10 mins, 37ºC for 120 mins and then 
85ºC for 5 mins in a Thermal Cycler Veriti (Applied Biosystems, Warrington, UK).  The 





Reverse Transcriptase-Polymerase Chain Reaction (qPCR).  Real-time quantitative 
PCR was performed with a reaction volume of 10 µl per qPCR tube (Alpha Laboratories 
Limited, Luton, UK).  The reaction volume was comprised of 5µl Ready Mix 2x, 0.5µl 
Forward Primers, 0.5µl Reverse Primers (all from a KiCqStart ® SYBR® Green Primers 
Kit (Sigma-Aldrich, Dorset, U.K)) and 4µl cDNA (in a 5:1 dilution with water).  The 
Forward and Reverse Primers used were for the following genes: Runx2, GLUT1, 
VEGFA, Tyrosine-protein kinase receptor (Tie2) and ribosomal protein L (RPL).  RPL 
was used as endogenous standard as it was found to have the most consistent expression 
level, when compared to β-actin and Glyceraldehyde-3-Phosphate-Dehydrogenase 
(GAPDH) (data not shown).  The expression for the gene of interest was normalized to 
RPL expression.  Relative expression for each target gene was calculated using the 
2−ΔΔCT method.  The Ct values of each target gene were normalized by the Ct of the 
housekeeping gene RPL to obtain the ΔCT values.  These values were subtracted by the 
Ct value of the calibrator which in this article is the MSCs seeded on DAR16-II free 
coated wells to obtain the ΔΔCT values.  This was performed in triplicates with the 
following cycler program:  1 cycle of 95°C–3min, 40 cycles of 95°C–10s and 60°C–20s, 
1 cycle of 95°C–1min, 55°C–30s, 95°C–30s using the VA703m Corbett (Corbett Life 
Science, Sydney, Australia). 
 
3.2.8 Culturing MSCs into Mesenspheres 
 
MSCs were cultured as floating spheres, mesenspheres, in a defined xeno-free MSC 
growth medium Mesenchymal Stem Cell Growth Medium DXF (PromoCell, Heidelberg, 
Germany).  Cells were seeded at 4000 cells per cm2 in a 5% CO2 incubator at 37°C for 1 
week to allow for mesenspheres to form.  Half media change was carried out twice a 




3.2.9 Osteogenic medium  
 
DXF medium was supplemented with 0.1µM dexamethasone (Dex), 0.05 mM ascorbic 
acid 2-phosphate (AsAP), and 10 mM glycerophosphate (Sigma-Aldrich, Dorset, U.K) 
for osteogenic differentiation.   
 
3.2.10 Mesenspheres differentiation  
 
Four types of coating conditions were compared: 1.DAR16-II coating (1:1 DAR16-II: 
Gelatine) with osteogenic media, 2. DAR16-II coating (1:1 DAR16-II: Gelatine) with 
DXF media, 3. Gelatine coating with DXF media (control) and 4.Gelatine coating with 
osteogenic media.  In 96 wells, 50 µl of each coating solution was added to its designated 
well and removed after covering the entire well.  Well were left to dry before seeding 
mesenspheres in a density of 6 mesenspheres per well.  100 µl of media was added to it 
designated well and left untouched for 9 days.   
 
3.2.10 Alizarin Red S Staining of Mesenspheres 
 
Mineralized matrix was stained with alizarin red S (1:100 in distilled water, adjusted to 
pH 4.2, and filtered) (Sigma-Aldrich, Dorset, U.K).  Mesenspheres were washed with 
PBS (Sigma-Aldrich, Dorset, U.K) and fixed in phosphate-buffered 4% 
paraformaldehyde (FD Neurotechnologies, INC, MD, USA) for 15 minutes.  
Mesenspheres were washed with distilled water and stained for 10 minutes followed by 
five washes in 50% ethanol (Sigma-Aldrich, Dorset, U.K), and air dried.  Mesenspheres 
were imaged using Olympus microscope with positive cells staining a bright, deep red 





3.2.11 Statistical analyses  
 
Results are expressed as mean ± standard deviation (SD).  Data were analysed using 
either On-way or two-way ANOVA with post hoc Tukey's Multiple Comparison to 
compare the means among groups.  GraphPad Prism 6.0c software (GraphPad Software 
Inc., La Jolla, USA) was used as the statistical software.  Significance was predetermined 
at α = 0.05.  Statistical differences were designated as significant if p-values were less 
than 0.05 (* p ≤ 0.05), and as highly significant if P-values were less than 0.01 (** p ≤ 









































3.3.1 Cell proliferation by total DNA content 
 
       
 
 
Figure 3.2 Total DNA content of MSCs seeded on DAR 16-II coated and non-coated BCP 
scaffolds at days 14 and 42.  Significant reduction of cell proliferation was detected at day 42 
in the non-coated scaffolds compared to DAR16-II coated scaffolds (p <0.001).  Cell 
proliferation with DAR16-II coating at day 42 was comparable to cell proliferation at day 14 
in coated scaffolds. Data represented as mean±SD, ( n=9). 
 
Total DNA content at day 14 showed that there was no significant difference in cell 
proliferation in the presence of DAR16-II coating.  However, a significant difference in 
the cell proliferation rate was observed in the presence of DAR16-II coating at day 42 
compared to non-coated scaffolds (p<0.001).  Moreover, the level of cell proliferation 
with DAR16-II coating at both time points; days 14 and 42 was comparable.  This 
suggests that DAR16-II preserves cell viability rather than induces cell proliferation 
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3.3.2 Cell differentiation by ALP activity 
  
                                   
                                       
                                                
 
Figure 3.3 ALP activity of MSCs cultured on BCP scaffolds in the presence and absence of 
DAR16-II coating.  No significant difference was observed between DAR16-II coated BCP 
scaffolds and non-coated scaffolds at days 14 and 42 of culture.  Data represented as 
mean±SD, (n=9). 
 
ALP production was used as an early indication of cell differentiation.  Figure 3.3 shows 
the ALP activity of MSCs cultured on BCP scaffolds with and without DAR16-II coating.  
No significant difference of ALP activity was found in presence of DAR16-II coating on 
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3.3.3 RUNX2 release from MSCs  
          
         
 
 
            
Figure 3.4 The amount of Runx2 released from MSCs cultured on BCP scaffolds with and 
without DAR16-II coating.  No significant difference in Runx2 release was observed with or 
without DAR16-II coating at days 14 and 42 of culture.  Data represented as mean±SD , 
(n=9). 
 
Runx2 is an early transcription factor involved in osteogenic differentiation.  Figure 3.4 
shows that no difference was detected between DAR16-II coated and non-coated 
scaffolds in Runx2 protein expression at days 14 and 42.  This suggests that DAR16-II 
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Figure 3.5  mRNA expression of Runx2, GlutI, VEGFA and Tie2 was analysed by 
quantitative-reverse transcription polymerase chain reaction (qRT-PCR).  Down regulation 
of Runx2, VEGFA and Tie2 gene expression was detected from MSCs cultured for 48 hrs in 
DAR16-II coated wells with non-conditioned media.  In addition, Glut1 gene was not 
expressed. Data represented as mean±SD  (n=3). 
 
qRT-PCR analysis showed that DAR16-II did not induce MSCs differentiations after 48 
hrs of culture (Figure 3.5).  Glut1 which is the earliest marker of osteogenic 
differentiation was not expressed. Runx2 expression which follows Glut1 during the 
osteogenic differentiation process was downregulated. Tie2, an early angiogenic marker, 
was downregulated as well as VEGFA gene expression; an endothelial-specific growth 
factor.  These results indicate that DAR16-II lacks both an angiogenic and osteogenic 
















Figure 3.6 MSC mesenspheres cultured in A) Gelatine coating with osteogenic media, B) 
DAR16-II coating with osteogenic media, C) DAR16-II coating with DXF media and D) 
Gelatine coating with DXF media. Mineralized matrix was stained in red colour. (x40 
magnification and bar= 20µm). 
 
Mineralization was detected using Alizarin red stain and it was observed only in the 
presence of osteogenic media (Figure 3.6 A and B).  However, the stain was more intense 
in the absence of the DAR16-II coating (Figure 3.6 A).  The DAR16-II coating was 
forming gelatinous islands in culture, and they were attached to floating mesenspheres. 
This might explain the less mineralization detected with the DAR16-II as they might have 
interrupted the spheroidal structure of the mesenspheres and affected their stemness.  In 
addition, no mineralization was detected in mesenspheres cultured in DAR16-II and 
gelatine coated wells without osteogenic media (Figure 3.6 C and D) further 






Biomaterials that can be used in bone engineering applications should have 
osteoconductive and osteoinductive properties.  Designer peptides in which SAPs were 
coupled to short osteogenic peptide motifs were used to induce osteoblasts proliferation, 
differentiation and cell migration (Horii et al., 2007, Kumada et al., 2010).  However, the 
use of pure SAPs in osteogenic differentiation applications has not yet been explored.  In 
this study, the direct osteogenic potential of pure DAR16-II was examined as a coating 
material in vitro for 3D printed BCP scaffolds.  MSCs cultured in non-osteogenic 
differentiating medium on DAR16-II coated scaffolds significantly preserved cell 
viability compared to non-coated scaffolds for 42 days of in vitro culture (Figure 3.2).  
This improved cellular response can be related to the DAR16-II hydrogel structure that 
mimics ECM structure.  Our results corresponded with Bokhari et al. findings in which 
the SAPs hydrogel structure enhanced osteoblasts proliferation suggesting that SAPs 
provide a 3D biomimetic environment that enhances cellular growth (Bokhari et al., 
2005).  However, neither osteogenic nor angiogenic markers were upregulated in MSCs 
cultured with DAR16-II coated BCP scaffolds or tissue culture plates in non-osteogenic 
media (Figures 3.3,3.4 and 3.5).  Moreover, mineralization was not observed with 
DAR16-II coated plates in non-osteogenic media without the presence of BCP scaffolds 
(Figure 3.6).  These data demonstrate that DAR16-II lack an osteogenic differentiating 
affect.  The SAPs 3D ultra-structure was compared to ECM in nanofiber dimension and 
porosity (Matrigel) (Gelain et al., 2006, Kirkham et al., 2007).  This might explain the 










The DAR16-II coating of BCP scaffolds preserved cell viability, demonstrating that 
DAR16-II can be used as a biomimetic hydrogel coating for BCP scaffolds.  It provides a 
smart matrix that can enhance cell biological responses over a long time point in vitro.  
The peptides hydrogel structure provides a 3D environment that maintains cells viability 
and support cell adhesion. As more cells are embedded within the 3D matrix, more cells 
can be involved in the regeneration process.  Also, the additional advantage of using this 
method is the ease of preparation of the peptide solution and the short time needed for 
scaffolds to be coated.  In addition, designed osteogenic motifs can be incorporated in the 
DAR16-II peptide sequence to induce specific cellular interaction.  Hence, DAR16-II 
coating can be used as a functionalizing coating material for all CaP scaffolds to enhance 






















































Angiogenesis is the process of growing new blood vessels out of pre-existing capillaries. 
Angiogenesis involves several steps 1) EC activation (tip cell selection) which leads the 
way of vessel branching upon pro angiogenic stimuli, 2) tip cell migration and stalk cells 
(ECs trail behind the tip cell) proliferation to elongate the sprout, 3) anastomosis of neo-
formed sprouts to form a functional network and 4) network pruning and remodelling 
(Potente et al., 2011).  First step in angiogenesis is the activation of EC to select a single 
cell becoming the tip of the sprout which migrate towards the pro-angiogenic stimulus 
(e.g. VEGF and Sphingosine-1-1phosphate, SP1) and probes the microenvironment via 
cytoplasmic protrusions called filopodia rich in VEGF Receptor 2 (VEGFR2, KDR) (De 
Smet et al., 2009, Lucke and Levkau, 2010).  KDR is the major VEGF receptor 
transducing angiogenic stimuli in EC via its kinase activity.  The growing (elongation) of 
the sprout is supported by proliferating EC called stalk cells that follow the trailing tip 
cell (Carmeliet and Jain, 2011).   
 
4.1.1 Notch signalling in angiogenesis 
 
The selection of a single tip cell versus the bulk of the stalk cells (lateral inhibition) is 
regulated by Notch signalling (Figure 4.1).  Briefly, tip cells (driven by VEGF signalling) 
express the membrane bound Notch ligand DLL4 which upon binding with Notch induces 
Notch intracellular domain (NICD) mediated signalling leading to inhibition of tip and 
promotion of stalk phenotype in the target cell (Phng and Gerhardt, 2009).  New vessel 
loop is formed when a tip cell contacts another vessel or another tip cell and the two 
branches are fused.  This branch fusion process is also supported by accessory cells such 
as pro-angiogenic Tie2 Expressing Monocytes/Macrophages (TEM) (De Palma et al., 




and Smooth Muscle Cells (SMC) provide vessel stability and regulate vessel perfusion 
during angiogenesis (Jain, 2003, De Palma and Naldini, 2009).  
 
 
Figure 4.1 Diagram showing sprouting angiogenesis.  Endothelial activation start with a tip 
cell (green) selection and stalk cells (blue) formation.  Tip cell guides the sprouting process 
and stalk cells follow the tip cell trail.  Tip cell fuses with another vessel or another tip cell to 
form a lumen (Adapted from Potente et al., 2011). 
 
Angiogenesis is either activated by tissue derived stimuli such as parenchymal/stromal 
cells derived GFs (e.g. VEGF, SP1 and ANG2) or hypoxia which activates an 
evolutionary conserved hypoxia responsive pathway (Hypoxia Inducible Factor, HIF) in 
EC and in other cells inducing angiogenesis and/or the production of pro-angiogenic 
cytokines (Holmes et al., 2007).  Overall, this angiogenic process drives EC to sprout in 
order to form new blood vessels and therefore support tissues’ oxygen and nutrients 
demand.  
 
4.1.2 Angiogenesis in endochondral bone ossification 
 
VEGF signalling is crucial for angiogenesis as demonstrated by several evidences 
(Shweiki et al., 1992, Carmeliet, 2005, Lucitti et al., 2012).  For this reason, therapies 
targeting VEGF or its receptors to block VEGF signalling have been developed and are 
used to limit angiogenesis in cancer and proliferative diabetic retinopathy (PDR) therapy 
with promising results but variable clinical outcomes (Titchenell and Antonetti, 2013) . 




engineering (TE) strategies (e.g. therapeutic angiogenesis of ischemic tissues).  
Importantly, it has been recently demonstrated that blood vessels/EC derived (angiocrine) 
signalling to stem or parenchymal cells is important to drive their differentiation and 
functions (Rafii et al., 2016).  At the same time, the cross-talk between EC, stromal and 
parenchymal cells induce EC specialisation into organ-specific EC.   
 
Angiogenesis have been demonstrated to be crucial during endochondral bone 
development (Gerber et al., 1999, Maes et al., 2002).  Inactivation of VEGF signalling 
through a soluble receptor chimeric protein (Flt-(1-3)-IgG), impaired endochondral 
ossification in juvenile mouse model (Gerber et al., 1999).  In particular, specific ECs 
have been identified during endochondral ossification, these cells are distinguishable 
from other bone ECs by their differential expression of CD31 (PECAM) and Endomucin 
(Emcn) (Kusumbe et al., 2014).  Furthermore, endothelial Notch activity has been 
demonstrated to differ in bone angiogenesis to other vascular beds (e.g. tumours) in 
which Notch inhibits sprouting angiogenesis (Ramasamy et al., 2014).  Disruption of 
Notch signalling by inducible inactivation of the Rbpj gene encoding RBP-Jk, an 
essential mediator of Notch-induced gene transcription, resulted in compromised bone 
vessels and defective bone development (Ramasamy et al., 2014).  This phenotype was 
rescued by the administration of recombinant Noggin which mediates the downstream 
effects of Notch signalling in EC during endochondral ossification.  
 
Overall, it is clear that promoting adequate angiogenesis is fundamental to achieve 
success in all tissue engineering strategies.  In the field of bone regeneration scaffolds are 
used to provide initial mechanical stability, to maintain space and to promote ossification.  
Therefore, inducing a functional vascular network within implanted scaffold is a major 




incorporating GFs within engineered scaffolds have been employed in animals with some 
success.  Nonetheless, all the strategies developed so far employ supra-physiological 
concentrations of GF which are released erratically and might lead to systemic side 
effects Genetic over-expression of VEGF in mouse skeletal progenitors led to excessively 
ossified bones (Maes et al., 2010).  Therefore, it is necessary to develop ways to provide 
adequate signalling delivered in spatiotemporal controlled manner to promote proper 
bone regeneration (Lee et al., 2011). 
 
4.1.3 The role of inflammatory cells in bone engineering 
 
Bone homeostasis is regulated by a dynamic balance between osteoblastic bone formation 
and osteoclastic bone resorption.  Osteoclastogenesis is controlled by the ratio of receptor 
activator of NF-κB ligand (RANKL) relative to its decoy receptor, osteoprotegerin (OPG) 
a potent physiological inhibitor of osteoclastogenesis (Teitelbaum, 2000, Khosla, 2001).  
Historically, osteoblasts were considered the source of OPG however,  it has been shown 
that B cells are the main source of bone marrow-derived OPG (Li et al., 2007, Pacifici, 
2010).  The importance of the immune system in inhibiting osteoclastogenesis in normal 
physiology, led to the shift towards the development of “smart” biomaterials able to 
modulate the immune response to improve bone regeneration  (Chen et al., 2014b, Franz 
et al., 2011).  These biomaterials activate specific immune response to develop a 
favourable osteogenic environment for bone cell recruitment and differentiation. 
Macrophages (Mf) are considered the most important immune cells which contribute to 
material-induced inflammatory reactions (Bartneck et al., 2012).  Mf also have a 
significant impact on bone physiology and pathology as they are OC precursors which 
mediate bone remodelling (resorption) and promote biomaterial degradation (Alexander 




and secreting osteogenic regulatory molecules such as BMP2 and transforming growth 
factor β (TGF-β) (Pettit et al., 2008, Honda et al., 2006, Wahl et al., 1990).  Mf are also 
required for bone mineralization as their depletion was found to reduce OB capacity of 
forming bone (Chang et al., 2008).  Furthmore, subsets of Mf have been demonstrated to 
promote angiogenesis by secreting pro-angiogenic growth factors, matrix-remodelling 
proteases and by interacting with endothelial cells sprouting and vascular network 
development (Fantin et al., 2010, Nucera et al., 2011).  Hence, recruiting inflammatory 
cells to the bone healing site is a critical step during bone development and repair.  
Finally, tissue resident osteal Mf have been recently identified and have been shown to be 
necessary for bone repair (Alexander et al., 2011). 
 
It has been shown that microenvironments developed by RAD16-II (the reverse sequence 
of  DAR16-II described in the present study)  promote vascular cell recruitment (Davis et 
al., 2005).  This was demonstrated by injecting a solution of RAD16-II in mouse 
myocardium resulting in the assembly of a nanofiber hydrogel.  This microenvironment 
promoted the recruitment of progenitor cells expressing endothelial markers (isolectin b4 
and CD31) and smooth muscle cells promoting the formation of functional vascular 
structures.  Therefore, since self-assembling peptides (SAPs) can create favourable 
microenvironments for endothelial cells recruitment, the objective of this study was to 
explore if the DAR16-II (described in chapter 2) could influence EC adhesion, phenotype, 
sprouting and morphogenesis as well as Mo/Mf attachment and polarisation. 
 
Aims of the study: 
1. Determine if DAR16-II can induce an angiogenic phenotype in HUVEC in vitro. 





4.2 Materials and methods 
 
4.2.1 Endothelial cell culturing 
 
Primary isolated human umbilical vein ECs (HUVECs; Promocell, Heidelberg, Germany) 
were cultured up to passage 6.  Cells were maintained in endothelial cell growth medium-
1 (EGM-1) (Promocell, Heidelberg, Germany) at 37°C , 5% CO2 and 95% humidity. 
 
4.2.2 Endothelial cell proliferation (MTT assay)  
 
The MTT assay is a colorimetric assay frequently used to assess cell metabolic activity; 
live cells exposed to MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] catalyse the reduction of this salt by mitochondrial enzyme, succinate 
dehydrogenase to a formazan, with a deep purple colour, the amount of formed formazan 
is proportional to the number of cells and to their metabolic activity.  Therefore, if the 
metabolic activity of cells is fixed, the MTT assay is used as an indirect method to assess 
cell number and then proliferation overtime.  A standard curve was generated by HUVEC 
at 5,10,15,20,25,50x103 (in 96 well plates) in triplicates.  The curve was established by 
charting cell numbers vs optical densities (OD) obtained by MTT treated wells.  This 
provided an equation linking OD to cell number/well.  To assess the effect of DAR16-II 
(previously described in chapter 2) on HUVECs proliferation, different coating 
concentrations of DAR16-II (in aqueous gelatine solution) were explored; 20, 25, 33, 50, 
57 %, (n=12).  HUVEC were seeded at a density of 5x103 cells per well in 96-well plates 
with 100µl of EGM-2 media (Promocell, Heidelberg, Germany) and incubated  at 37 ⁰C, 
5% CO2.  After 24 hrs, media was replaced with 100µl/well of MTT solution (5% w/v 
MTT in PBS added 1:10 to ascorbate free media).  The plates were incubated for 4 hrs 




with DMSO (Sigma-Aldrich, Dorset, U.K) 100µl per well under shaking for 5 min.  
Absorbance was measured on a DYNEX plate reader (Dynex Technologies, Chantilly, 
VA, USA) (test wavelength: 570 nm; reference wavelength: 630 nm). 
 
4.2.3 Endothelial cell spreading 
 
To investigate the effect of DAR16-II on HUVECs adhesion, 48-well plate was coated 
with DAR16-II: gelatine at 1:1 ratio (or gelatine as control).  Cells were seeded at a 
density of 2x103 cells per well in EGM-1 (Promocell, Heidelberg, Germany) for 30 min.  
After that, media was removed and wells were washed twice with PBS (Sigma-Aldrich, 
Dorset, U.K) fixed in 2% buffered PFA (FD Neurotechnologies, INC, MD, USA) for 15 
minutes and blocked in 1% Foetal bovine serum (FBS) in PBS for 15 minutes at 37°C.  
Wells were rinsed with PBS then treated with PBS-buffer 0.1% Triton X-100 (Sigma-
Aldrich, Dorset, U.K) for 2 min to permeabilise the cell membranes. Actinic cytoskeleton 
was stained with TRITC-conjugated Phalliodin (Molecular Probes, USA) was added to 
localise actin microfilaments of attached HUVECs in 1:1000 dilution in PBS for 45 min 
at room temperature (RT).  The wells were washed three times with PBS before nuclear 
counterstaining using Höechst 33342 (ThermoFisher Scientific, Paisley, UK) at 1µg.mL-1 
for 10 mins at RT.  Finally wells were washed twice with PBS (Sigma-Aldrich, Dorset, 
U.K) and visualized with a wide field inverted microscope equipped with charged-
coupled device (CCD) camera to capture photographic images using CellSens software 
(Olympus IX51, Biosystems, Munich, Germany).  The surface area of attached cells were 





4.2.4 Endothelial cell morphology 
Standard 22x22 mm square coverslips (VWR, PA, USA) were coated either with gelatine 
or gelatine:DAR16-II (1:1) in 6-well plates.  Slides were micro-seeded with 3x104 
HUVECs per slide in 50 µl and left to attach for 30 min at 37°C in a 5% CO2 atmosphere.  
Next, 1.5 ml of EGM-1 was added to each well and slides were maintained at 
37°C/5%CO2 atmosphere.  After 48 hours, media was removed and slides were fixed and 
stained as previously described.  Coverslips were mounted on standard histological slides 
in Mowiol® 4-88 (Sigma-Aldrich, Dorset, U.K) and visualized with an Olympus 
microscope to quantify the relative abundance of different cell phenotypes (determined by 
cell morphology ) (Olympus Biosystems, Munich, Germany).   
 
4.2.5 Angiogenic assay 
 
Matrigel is an ECM extract derived from mouse Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma cells and frequently used to assess the EC potential in forming tubular structures 
in vitro.  Four different coating conditions were prepared in 96 well plates.  The first 
group was coated with gelatine as a control while the second was coated with 1:1 
gelatine:DAR16-II.  The third was coated with 1:1 gelatine:BCP (15% HA and 85% TCP 
powders, Sigma, UK).  The last was coated with 1:1 (gelatine:BCP):DAR16-II.  Matrigel 
(Corning, Netherlands) was thawed on ice and mixed with EGM-2 in a 1:1 ratio.  Then 
the Matrigel solution was mixed with each group in 1:1 ratio and 50µl of each solution 
was transferred into its designated well in 96-well plate and incubated at 37°C in a 5% 
CO2 atmosphere for 30 min.  EC suspension (1x104 HUVEC/well in EGM-2 pre warmed 
at 37°C) was added to each well.  After 24 hours, results were visualised and imaged as 
previously described.  Images were analysed to assess tubule-like structures length and 




4.2.6 RT2 Profiler PCR Arrays 
 
RT2 Profiler PCR Array is a low density qRT-PCR based array (PAHS-024Z, Qiagen, 
UK, profiles 84 genes key in EC biology and angiogenesis).  2x105 HUVECs were seeded 
in T25 gelatine and 1:1 gelatine:DAR16-II coated flasks (Greiner Bio-one CELLSTAR®, 
Frickenhausen, Germany).  Cells were maintained in EGM for 48 hours at 37°C in a 5% 
CO2 atmosphere.  Total RNA was isolated by using the method described in chapter 3.  
cDNA was prepared by retro transcribing 1 µg of total RNA using the RT2 qPCR Array 
First Strand Kit in accordance with the supplier instructions (Qiagen, Crawley, UK). The 
template was mixed with RT2 SYBR Green/Fluorescein PCR master mix (Qiagen, 
Crawley, UK).  10 µl were added to each well of the RT2 qPCR profiler plate containing 
SYBR green-optimized primer assays for 84 genes related to angiogenesis (see 
Appendix).  Five housekeeping genes, controls for genomic DNA contamination, RNA 
quality and general PCR performance were included in the array.  The thermal cycling 
conditions were 10 min at 95 °C followed by 40 cycles at 95 °C for 15 s and then 60 °C 
for 1 min. The data were collected using Bio-Rad CFX384 analytical thermal cycler (Bio-
Rad Laboratories, USA).  Control and positive PCR controls were within the accepted 
range.  Threshold cycle values were analyzed using the ΔΔCt method using the PCR 
Array Data Analaysis Web portal at www.SABiosciences.com/pcrarraydataanalysis.php   
 
4.2.7 THP-1 cell culture  
 
THP-1 monocytes, human monocytic leukaemia cells (ATCC®, Teddington, UK) were 
cultured in a Roswell Park Memorial Institute-1640 medium (Gibco, Gaithersburg, 
Maryland, USA) supplemented with 10% FBS, 100µg/ml penicillin, 100µg/ml 
streptomycin and 2mM Lglutamine (all from Sigma-Aldrich, Dorset, U.K).  Cells were 




passaging, cells were counted in a 1:1 dilution with filtered trypan blue (ThermoFisher 
Scientific, Paisley, UK) using an automated cell counter (TC10, Bio-Rad, Hemel 
Hempstead, UK).  The tube was subject to centrifugation for 30 min at 2000rpm at RT 
with soft acceleration and deceleration settings activated.  The cloudy interface of cells 
was removed by pipette, centrifuged and re-suspended. 
 
4.2.8 THP-1 differentiation 
 
To obtain macrophages, THP-1 monocytes can be differentiated into THP-1 derived Mf 
(M0 phenotype) using phorbol 12-myristate 13-acetate (PMA) (Park et al. (2007).  PMA 
medium consisted of Dulbecco’s Modified Eagle Medium (DMEM) (phenol red free), 
PMA at a concentration of 5 ng/ml, 10% FBS, 2mM L-glutamine, 100µg/ml penicillin 
and 100µg/ml streptomycin (all from Sigma-Aldrich, Dorset, U.K).   
 
4.2.9 Macrophage and DAR16-II culture 
 
6-well plates were coated with 1:1 gelatine:DAR16-II and gelatine (control) as before.  
THP-1 cells were seeded at a density of 5x105 per well in PMA medium.  Cells were 
maintained for 48 hrs at 37°C in a 5% CO2 atmosphere.  For RNA extraction, media was 
removed and attached cells were washed twice with PBS (Sigma-Aldrich, Dorset, U.K).  
300 µl Tri-reagent was added directly to wells, RNA was extracted and then retro 
transcribed into cDNA as described in chapter 3.  The Forward and Reverse Primers used 








Target gene Forward primer Reverse primer 
Glut1-1 AACTCTTCAGCCAGGGTCCAC CACAGTGAAGATGATGAAGAC 
VEGFA AATGTGAATGCAGACCAAAG GACTTATACCGGGATTTCTTG 
MRC1 AAATTTGAGGGCAGTGAAAG GGTTTGGAGTTTATCTGGTAG 
RPL CGCTCACAATGTTTCCTCCA TGACTCTGATGGCCAGTTGG 
 
Table 4-1 Primer pairs used for qRT-PCR. 
 
4.2.10 Macrophage attachment 
 
96-well plates were coated with 1:1 gelatine:DAR16-II and gelatine (control) overnight.  
Cells were seeded at a density of 1x103 cells per well in 100 µl of EGM-1 media 
(Promocell, Heidelberg, Germany) for 30 min at 37°C/5%CO2 atmosphere.  Wells were 
washed three times with PBS (Sigma-Aldrich, Dorset, U.K) and fixed as previously 
described.  The nuclei of attached cells were stained with Hoeschst 33342 (ThermoFisher 
Scientific, Paisley, UK) at 1µg.mL-1 concentration for 10 mins at RT.  Next, wells were 
washed twice with PBS and visualized with an Olympus microscope and attached cells 
were counted (Olympus IX51, Biosystems, Munich, Germany).  
 
4.2.11 Statistical analysis  
 
Results are expressed as mean ± standard deviation (SD).  Data were analysed as follows:  
1.One-way ANOVA with post hoc Dunnett's multiple comparisons test to compare the 
means of the test groups to the mean of the control group (HUVECs proliferation and 
THP-1 qPCR studies) 2. Two-way ANOVA with post hoc Tukey's multiple comparisons 
test to compare means among groups (cell morphology and angiogenesis assay studies), 
3. Two-tailed t-test with Wilcoxon-Mann-Whitney test (HUVECs spread and THP-1 




USA) was used as the statistical software.  Statistical differences were designated as 
significant if p-values were less than 0.05 (* p ≤ 0.05), and as highly significant if P-











































4.3 Results  
4.3.1 EC proliferation  
In order to determine the effect of DAR16-II on EC proliferation, a 48 hrs proliferation 
assay was performed. 5x 103 HUVECs were seeded on 96 wells plate coated with gelatine 
or a mixture of gelatine and DAR 16-II at different ratios (20 to 75% DAR 16-II). 
Furthermore, on the day of the experiment, 5-10-20-40-80 X103 cells were seeded in 
separate gelatine coated plate to generate a standard curve. MTT assay was used as an 
indirect measure of cell number by relating absorbance measurements with cell number 
through the standard curve.  
 
                
Figure 4.2 48 hrs HUVECs proliferation. Exposure of HUVEC to different DAR16-II 
concentrations inhibited proliferation (p<0.0001).  Data represented as mean±SD, (n=12). 
 
The results showed that, in comparison to gelatine, DAR16-II inhibits HUVECs 
proliferation at all concentrations.  No dose/response correlation could be observed with 




reduced inter-sample variability (Figure 4.2).  Previous observations support the idea that 
DAR16-II forms agglomerates on tissue culture plastic leaving zones of uncoated plastic. 
This effect is reduced with higher peptide’s concentrations.  This could justify the 
proliferation results indicating that a more homogeneous coating can affect a larger 
percentage of cells and therefore produce more consistent results.  Proliferation was 
reduced by about Δ66% with DAR16-II and this was compatible with either a migratory 
(tip) or a quiescent (phalanx) EC phenotype.  Consequently, 50% DAR 16-II 






















4.3.1 Endothelial cell adhesion and spreading 
 
In order to determine if DAR16-II has an influence on early EC adhesion, HUVECs were 
seeded on 1:1 gelatine/DAR16-II coated wells for 30 min and compared to cells seeded 




     
     
     
 
Figure 4.3 Cell attachment assay showing the effect of DAR16-II on HUVECs adhesion.  It 
showed that the average cell area of attached HUVECs was significantly higher (about 
160%) with DAR16-II after 30 min of incubation (p< 0.0001).  Data represented as 
mean±SD, (n=12). 
 
The average cell area of HUVECs that adhered at this early time point was comparable on 
both substrates but HUVECs spreading was markedly higher (about 160%) in the 
presence of DAR16-II (p<0.0001).  This data suggests that DAR16-II may partially exert 





4.3.3 Endothelial cell morphology  
 
Morphology is indicative of EC functions in particular quiescent EC (resembling in vivo 
phalanx EC) are polygonal, mostly well juxtaposed to each other, slowly proliferating and 
devoid of lamellipodia or filopodia. (Potente et al., 2011).  In contrast, activated, 
migratory EC (resembling in vivo tip EC) are elongated, often isolated, non-proliferating 
and presenting filopodia and lamellipodia.  Finally proliferating stalk-like EC have a 
polygonal morphology and are smaller.  From previous proliferation data (Figure 4.2) we 
inferred that DAR 16-II might promote a tip-like or a phalanx-like phenotype.  To 
determine whether DAR16-II could indeed induce the morphological features typical of 
tip or phalanx cells we examined and quantified morphology of EC seeded on DAR 16-II 
in comparison to gelatine.  HUVECs were cultured on slides coated with DAR16-II and 
gelatine and stained with TRITC-conjugated Phalloidin (staining actinic cytoskeleton) 
and Höechst (nuclei) (Figure 4.4).  The relative abundance of tip and phalanx cells, 
defined as above, was quantified.  The results demonstrated clear morphological 
differences in HUVECs cultured with DAR 16-II which on average, appear more 
elongated, isolated and produced more filopodia and lamellipodia indicating a more 
migratory phenotype in comparison to gelatine.  The quantifications performed confirmed 
these findings showing a prevalence of quiescent/proliferating HUVECs (peripheral actin, 
contacting juxtaposed cells) on gelatine and a prevalence of migratory (tip) EC in 
presence of DAR16-II.  These data in combination with those obtained with proliferation 
assay suggest that DAR16-II induced a migratory non-proliferating phenotype in 







Figure 4.4 Cytoskeletal staining (Phalloidin (red) for actin and of Hoechst (blue) for nuclei) 
of HUVECS cultured on DAR16-II and gelatine coated slides for 48 hrs. A) and E) Show the 
cell morphology of HUVECs cultured on gelatine with quiescent phenotype with abundant 
peripheral actin cells.  B) and D) show less peripheral actin in HUVECs cultured on DAR16-
II with more lamellipodia and filopodia.  C) Shows the quantification of the different cell 
phenotypes associated with DAR16-II and gelatine. HUVECs with more filopodia, 
lamellipodia and less peripheral actin were detected with DAR16-II compared to gelatine.  
(20x magnification, A.B,D scale bar=40µm and E scale bar=20µm). 
 
4.3.3 Angiogenic assay 
 
Considering previous data suggesting angiogenic EC activation, Matrigel morphogenesis 
assay was used to determine if DAR16-II has the potential to promote the formation of 
tubular-like structures.  Moreover, BCP powder was added as a second variable to 








Figure 4.5 Matrigel assay comparing tubular-like structures developed with 1) Gelatine, 2) 
Gelatine+BCP, 3) Gelatine+DAR16-II and 4) Gelatine+BCP+DRA16-II.  A) HUVECs 
cultured in Gelatine+DAR16-II resulted in significantly longer tubular-like structure 
formation compared to other conditions (p<0.01). B) HUVECS cultured in 
Gelatine+DAR16-II resulted in significant increase in number of nodes compared to other 
culturing conditions (p<0.001). Data represented as mean±SD, (n=3). 
 
By comparing the length and number of nodes of tubular-like structures developed in 
Matrigel containing: 1) Gelatine, 2) Gelatine and BCP, 3) Gelatine and DAR16-II and 4) 
Gelatine, BCP and DAR16-II.  It was found that the 1:1:2 combination of gelatine, 
DAR16-II and Matrigel produced the longest and more complex networks.  Both tubular 
length and number of nodes were significantly higher (p<0.001) with gelatine+DAR16-II 
compared to structures developed with the other culturing conditions (400% in 
comparison to gelatine only control).  The presence of BCP in Matrigel did not enhance 
tubular-like structures formation.  These data are compatible with previous ones, 
indicating an overall EC activation toward an angiogenic phenotype in the presence of 






4.3.4 RT2 Profiler PCR Arrays 
To identify the molecular effectors responsible for the observed phenotype a low density 




in different angiogenic pathways. 
 
Figure 4.6 Clustergram RT2 Profiler PCR Array of genes expressed by HUVECs cultured 
on DAR16-II and gelatine (control) coated flasks for 48 hrs.  The graph demonstrates that 










Figure 4.7 Scatterplot of RT2 Profiler PCR Array of genes overexpressed (red) and under-
expressed (green) by HUVECs following 48 hrs of culture on DAR16-II and gelatine 
(control) coated flasks, (n  =  2). 
 
 
The array clustergram showed that the genes expressed by each group (DAR16-II or 
gelatine) were consistently equivalent (Figure 4.6).  In addition, it showed that the 
exposure of HUVECs to DAR16-II in un-stimulated culture conditions lead to different 
gene expression profile compared to gelatine (control).  Although the more classical 
angiogenic pathways (e.g. VEGF) were not activated and corresponding genes were not 
overexpressed, Endoglin (ENG) was among the few overexpressed genes (2.6 fold 
change) in the presence of DAR16-II (Figure 4.7).  ENG is essential for angiogenesis and 
it is involved in a pro-angiogenic endoglin/transforming growth factor-β (TGF-β) 
signalling pathway (Bergers and Hanahan, 2008).  Moreover, a significant increase in 




SERPINE1 expression promotes angiogenesis of cancer cells (Pavón et al., 2016).  In 
addition, a significant increase in the production of ACTB is indicative of cytoskeleton 
remodelling and rearrangement which is compatible with a migratory phenotype of ECs 
subjected to DAR16-II (Bunnell et al., 2011).  VEGF receptor I (Flt1, non-transducing 
decoy receptor) and VEGF receptor II (KDR, kinase receptor responsible for the majority 
of VEGF responses in HUVECs), were reduced. Nonetheless, Flt1 was reduced by 7 folds 
while KDR was barely down-regulated (-1.7 fold).  This might suggest that HUVECs 




                
Figure 4.8 THP-1 adhesion assay showing the effect of DAR16-II on cell attachment 
compared to gelatine after 1hr of culture. The number of attached THP-1 too DAR16-II was 




            
Figure 4.9  mRNA expression of GLUTI, VEGFA and MRC1 was analysed by quantitative-
reverse transcription polymerase chain reaction (qRT-PCR).  No variations in gene 
expression were detected in THP-1 cultured for 48 hrs with non-conditioned media. Data 
represented as mean±SD , (n=3). 
 
Since, monocytes/macrophages are essential for initial tissue response upon injury and 
have been demonstrated to elicit a pro-angiogenic effect, experiments were performed to 
assess monocytes (THP1 model) responses to DAR16-II.  Initially, results indicated that 
DAR 16-II promotes THP1 adhesion similarly to what happens with EC suggesting an 
ability of DAR 16-II to promote monocytes recruitment (Figure 4.8).  Gene expression 
analysis to assess THP-1 polarisation revealed that THP-1 exposure to DAR16-II for 48 h 
did not induce neither osteogenic (Glut-1) nor angiogenic (VEGFA) activation (Figure 
4.9).  In addition, the M2 macrophages polarization marker (MRC1) was not affected by 
DAR16-II.  Since these experiments were performed on monocytes only (naïve THP1 
without previous differentiation into macrophages with PMA) gene expression analysis is 










4.4 Discussion  
 
Angiogenesis is induced when ECs are subjected to pro-angiogenic signals e.g. VEGF.  
Activated ECs project filopodia (enriched in KDR) and become motile tip cells which 
migrates toward the pro-angiogenic stimulus (Potente et al., 2011).  Stalk cells follow the 
tip, proliferate to support sprout elongation and establish a lumen.  During angiogenesis, 
cells shuffle between tip and stalk cell phenotypes in dynamic cycles of sprouting and 
tubulogenesis (Phng and Gerhardt, 2009, Eilken and Adams, 2010).  This process is 
terminated when pro-angiogenic signal is ceased and quiescence is restored (Potente et 
al., 2011).  The data presented in this study supports the idea that DAR16-II promotes a 
pro-angiogenic switch in ECs.  The results presented in this study demonstrate that 
DAR16-II promote better EC adhesion (Figure 4.3) which is compatible with faster 
angiogenesis in vivo.  Furthermore, our results showed that cell proliferation was 
significantly reduced upon exposure to DAR16-II and that proliferation rate was not 
affected by different concentrations (ranging from 20 to 75%) (Figure 4.2).  These results 
indicate that the mere exposure to DAR16-II could induce a phenotype switch in EC.  
This was investigated by morphological analysis of HUVECs exposed to DAR16-II.  
Cytoskeletal staining showed a different phenotype associated with DAR16-II with more 
distinct lamellipodia and filopodia observed (Figure 4.4).  Endothelial migratory 
processes are characterized by the filopodia and lamellipodia projections.  Filopodia are 
thin membrane extensions that contain long parallel actin filaments and act as sensors to 
motility stimuli (Lamalice et al., 2007).  Lamellipodia are cytoplasmic protrusions that act 
as a guiding point for spreading and migration (Small et al., 2002).  These data suggest 
that indeed, exposure to DAR16-II promote a more migratory (tip-like) phenotype in EC.  
In order to explore the effect of DAR16-II on EC morphogenesis, HUVECs were seeded 
on Matrigel mixed with DAR16-II.  DAR16-II was found to promote tubular-like 




of Narmoneva et al. in which self-assembly peptides RAD16-II induced both capillary-
like networks formation and ECs attachment (Narmoneva et al., 2004).  DAR16-II in 
Matrigel significantly stimulated longer and more interconnected tubular network (Figure 
4.5 A and B).  Finally, in order to determine the molecular mechanism of the observed 
functions, a qRT-PCR based array was used to screen the genes involved in angiogenic 
pathways.  Three genes were significantly up-regulated in DAR16-II treated EC in 
comparison to gelatine treated ones which were ENG also known as CD105, SERPIN1 
and ACTB (Figure 4.7).   
 
ENG is a homodimeric transmembrane glycoprotein highly expressed on angiogenic EC 
surface and acts as a co-receptor to TGF- β which regulates angiogenesis through 
balancing pro-proliferative and pro-differentiation pathways of EC (Dallas et al., 2008, 
Park et al., 2013).  This is achieved through balancing signals of TGFb-receptor II 
(TGFbRII) and two TGFbRI (Activin-receptor like kinase-1 (ALK1) and ALK5) 
pathways (Lutty et al., 1993, Oh et al., 2000, Seki et al., 2003, Lu, 2008).  ENG binds to 
TGF- β phosphorylate ALK1 and ALK5 which phosphorylate downstream Small mothers 
against decapentaplegic (Smad) proteins inducing an angiogenic phenotype (Pérez-
Gómez et al., 2010).  Decreased ENG expression leads to distorted angiogensis in vitro 
and results in defective vascular development in vivo (Arthur et al., 2000, Bourdeau et al., 
2000).  Mutations in ENG and ALK1 result in hereditary haemorrhagic telangiectasia 
(HHT) in human, an arteriovenous disease characterized by malformed vessel walls 
(Pardali et al., 2010).  On the other hand, SERPINE1 expression promotes spreading, 
migration and angiogenesis of cancer cells (Pavón et al., 2016).  As SERPINE1 
expression enhances cell migration, it also reduces cell proliferation simultaneously 
(Czekay et al., 2011, Pavón et al., 2015).  Both ENG and SERPINE1 expression are 




expression is modulated by TGF-β1 and SMAD proteins (Pavón et al., 2016).  The over-
expression of ACTB is also an indicative of migratory phenotype of ECs (Figure 4.7) 
(Bunnell et al., 2011).  Taken together, DAR16-II induction of migratory gene 
expressions after 48 hrs of culture proposes that DAR16-II acquires a proangiogenic 
potential.  DAR16-II was also found to significantly induce THP-1 adhesion; a 
macrophage model (Figure 4.8).  Macrophages support vessel development by facilitating 
fusion during angiogenesis (Potente et al., 2011).  However, the lack of essential 
cytokines in the THP-1 culturing medium might explain the absence of differentiating 








































In previous studies the use of SAPs with the RADA motif were found to promote 
angiogenesis when used as a 3D scaffold, the exact mechanism was not determined 
(Genové et al., 2005, Narmoneva et al., 2005).  In this study, DAR16-II (a reverse 
sequence) was found to induce an angiogenic effect.  DAR16-II promoted EC spread, 
migration, tubular-like structure formation and THP-1 attachment.  Results have shown 
that DAR16-II mediated effects on EC might be derived from activation of ENG, 
SEPINE1 and ACTB pathways.  This data has to be confirmed with further studies.  The 
presented data also suggests that DAR16-II affects Mo adhesion, which allows 
speculation regarding an immunomodulatory effect.  Nonetheless, this has to be 




































































The main aim of the present study was to develop a biologically active bone scaffold able 
to promote early vascularization of the construct and, inherently, of the angio-osteogenic 
coupling i.e. bone formation.  The potential osteoconductive and osteoinductive effects of 
3D printed scaffolds of different pore size and geometries whose surface was 
functionalised with a novel SAP (DAR16-II) was firstly investigated in vivo by CSD 
calvaria rabbit model.  Although there is no unanimous agreement in the literature on the 
pore shape that could improve bone development within scaffolds, different studies have 
shown better outcome in both bone development and vessels ingrowth with circular 
surfaces (Zadpoor, 2015).  However, our data revealed that there was no significant 
difference between round and square pores in inducing bone formation (Chapter 2, 
Figures 2.8 and 2.9).  According to Rumpler et al. which compared different pore 
geometries in scaffolds for bone regeneration (Figure 5.1) all tissue ‘fronts’ would 





Figure 5.1 (a) Staining of actin stress fibres developed in vitro by MC3T3-E1 cells in 
different channel geometries of HA plates with phalloidin-FITC; (i) triangular, (ii) square, 
(iii) hexagonal and (iv) round shape channels, the tissue regeneration process based on a 
linear curvature-dependent theoretical mode was depicted in subfigure (b). The lines (early 
time point 1, ongoing times 2 and 3 of 21 and 30 days) mark the simulated development of 





The same finding was supported by a study from Van Bael et al. in which human 
periosteum-derived cells (hPDC) after 14 days of culture in vitro resulted in circular 
filling of different pore geometries including triangular, hexagonal and rectangular 
titanium scaffolds (Van Bael et al., 2012).  Hence, our result agrees with their conclusion 
in that bridging behaviour of cells is geometry independent.  However, Van Bael et al. 
claimed that the pore size was key in bone regeneration with more neo-formed bone 
associated with 1000 µm pore size compared to 500 µm but more ALP activity with 500 
µm pore size (Van Bael et al., 2012).  They suggested that the effect mediated by smaller 
pore (ALP activity) could be justified by enhanced cell adhesion.  Our findings contradict 
this assumption by showing no significant difference between total neo-formed bone and 
the bone formed in direct contact with the biomaterial in 400 and 800 µm pore size 
scaffolds (Chapter 2, Figures 2.8 and 2.9).  However, the model employed (in vivo) 
differs significantly from the one used by Van Bael and colleagues (in vitro) and this may 
explain the different outcomes.  Interestingly, DAR16-II coating showed curious results 
of enhancing both the total bone formation and more evidently the bone in direct contact 
with the biomaterial.  To our best knowledge, this is the first study to examine the use of 
SAPs as a surface coating for BCP functionalization.  Our findings suggest that by 
coating BCP scaffolds with DAR16-II it is possible to promote better bone formation than 
utilising 3D printed BCP scaffolds alone. 
 
The aim of the following studies was to investigate how this proactive factor induced a 
biological response and resulted in more bone formation.  By testing the effect of 
DAR16-II on MSC differentiation in vitro, there was no upregulation of either osteogenic 
or angiogenic genes expression (Chapter 3, Figure 3.5).  Also, the lack of osteoinductive 
property was demonstrated by alizarin red staining showing no calcium deposits with 




MSCs on BCP scaffolds coated with DAR16-II did not induce osteogenic differentiation 
(Chapter 3, Figures 3.3 and 3.4).  However, DAR16-II significantly maintained cell 
viability compared to non-coated scaffolds (Chapter 3, Figure 3.2).  These results suggest 
that the DAR16-II coating of BCP enhances the cell behaviour.  The RADA-and 
RARADADA- based SAPs are supposed to mimic the RGD peptides sequence and 
provides a nanoscale environment similar to ECM that promote cell adhesion and 
proliferation (Gelain et al., 2007).  This was demonstrated by Bokhari et al. as they used 
RAD16-1 (PuraMatrixTM, self-assembly peptide with a reverse single RADA- motif 
sequence) to coat PolyHIPE polymer (PHP) (Bokhari et al., 2005).  OBts cultured on 
RAD16-1 coated scaffolds showed a significant increase in cell proliferation during the 
35 days of in vitro culture.  Also, it was confirmed by Gelain et al. by studying the 
relation of neural precursor cells to RAD16-I scaffolds and found that cells were fully 
embedded in the peptides nanofibers in an analogous microenvironment to ECM structure 
(Gelain et al., 2006).   
 
As the DAR16-II shares the basic peptide compartments of RAD16-II in a reverse 
sequence, we assumed that they might share the same biological properties in promoting 
angiogenesis (Narmoneva et al., 2004, Narmoneva et al., 2005).  Our in vitro data 
demonstrated this assumption.  Indeed, culturing HUVECs with DAR16-II significantly 
reduced cell proliferation suggesting more cells were undergoing activation and 
differentiation (Chapter 4, Figure 4.2).  This was confirmed by significantly promoting 
tubular-like structure formation and cell adhesion (Chapter 4, Figures 4.3and 4.5).  In 
addition, DAR16-II induced the formation of filopodia and lamellipodia thus 
demonstrating the activation of EC by inducing migratory phenotype (Chapter 4, figure 
4.4).  These results were broadly consistent with Narmoneva et al. study as they showed 




promoted long-term cell survival and capillary-like network formation in 3D cultures of 
human microvascular endothelial cells isolated from fat tissue in vitro.  They showed that 
RAD16-II enhanced VEGF gene expression; however the mechanism in which the SAP 
was inducing angiogenesis was not investigated.  In our study, angiogenesis PCR array 
showed that three angiogenic genes were significantly upregulated by DAR16-II 
including; ENG, SERPIN-1 and ACTB while the VEGF decoy receptor Flt1 was down-
regulated (Chapter 4, Figure 4.7).  This down-regulation suggested that EC could be in a 
more active state ready to transduce VEGF signalling upon exposure.  This also might 
agree with Narmoneva et al. finding although VEGF was not up-regulated in our study. 
Our results confirm that SAPs nanostructure influence cell adhesion and EC activation 
observed by other groups.  Nonetheless, our results on EC indicated an inhibition rather 
than induction of proliferation thus highlighting that the different sequences are exerting 
different effects.  On the basis of our RNA array data, we propose that the specific effects 






Figure 5.2 The proposed mechanism of DAR16-II in inducing endothelial cell migration. 
DAR16-II activates ENG expression which is a co-receptor to TGF-β.  This phosphorylates 
a SMAD downstream through ALK1 activation which induces angiogenesis in endothelial 
cells. SERPINE1 overexpression upon exposure to DAR16-II is thought to activate the 
SERPINE1 pathway in inducing endothelial migration through MMP activation.  In 
addition, as SERPINE1 is activated by TGF-β during angiogenesis, the DAR16-II activation 
of SERPINE1 might be regulated by expressing TGF-β through ENG.   
 
RNA array data also demonstrates an up-regulation of ACTB expression which is 
compatible with the observed migratory phenotype of ECs (Bunnell et al., 2011).  These 
results suggest that DAR16-II can induce angiogenesis via both ENG mediated signalling 
and by preparing EC for higher responsiveness to VEGF signalling.  In addition, DAR16-
II significantly enhanced THP-1 adhesion, which suggests that DAR16-II might have an 
effect on monocytes recruitment in vitro (Chapter 4, Figure 4.8).  We can speculate that 
this might also reflect into an immuno-modulatory effect on macrophages but to 




THP-1 differentiation into macrophages in the limited model (without cytokines added) 
used in this study (Chapter 4, Figure 4.9).   
 
Overall our experiments have demonstrated for the first time that SAP and DAR16-II in 
particular is a viable substrate to functionalize the surface of scaffolds for bone 
engineering.  The DAR16-II coating was able to provide a functioning matrix which 
promoted better osteogenesis in vivo.  Furthermore, this work demonstrated that the 
observed in vivo effects might be mediated by better cell (inflammatory, mesenchymal 
and endothelial cells) recruitment from the neighbouring healthy tissue.  Additionally, the 
in vitro data demonstrated a clear angiogenic effect on EC, due to osteo-angiogenic 
coupling, which can justify the observed increase in bone regeneration.  The histo-
morphometric analysis performed in this study highlights an increase in bone formation in 
DAR16-II functionalized scaffolds.  Comparing the data of overall bone formation vs the 
bone in contact with biomaterial only, it is possible to infer that the observed effects were 
mainly mediated by the direct contact with DAR16-II adsorbed on the BCP surface rather 
than a diffusion of DAR16-II within the pores.  Thus it was hypothesized and partially 
demonstrated that DAR16-II provides a supporting environment for cell attachment and 
interaction leading to enhancing the bone regeneration process around BCP scaffolds.   
 
The work in this thesis has demonstrated that DAR16-II is able to provide a functioning 
matrix as a coating material.  It induced the osteogenic capability of BCP scaffolds in vivo 
as well as maintaining cell viability on coated BCP scaffolds in vitro.  It has a direct 
angiogenic effect on endothelial cell activation and on inflammatory cell attachment.  
Thus it provides a supporting environment for cell attachment and interaction in order to 
enhance the bone regeneration process.  The long-term effect of DAR16-II in coating 




formation.  However, the mechanism of action requires more studies to confirm the 
proposed hypothesis to identify the molecular mode of action.  In addition, identifying the 











































































The BCP scaffolds used in this study were 3D printed using the robocasting (DW) 
methodology.  Coating of 3D printed scaffolds was obtained by simple immersion into a 
0.15% solution of DAR16-II, this strategy alone (without chemical crosslinking of the 
SAP to BCP surface) was able to exert the observed effects.  Therefore, this study shows 
promising results for developing commercial off- the shelf functionalized scaffolds with 
very limited costs translating these discoveries into the clinical arena.  A further asset of 
this proposed strategy is that the scaffolds can be 3D printed to any shape.  This coupled 
with high resolution imaging of bone defects can pave the way to the realisation of 
personalised patient specific scaffolds.  
 
A limitation of this study was that the cell/molecular mechanism of action of DAR16-II 
was only partially addressed.  Therefore, further studies are warranted to confirm the 
proposed hypothesis, to identify the molecular mechanisms driving enhanced 
osteogenesis and finally to tailor even more effective strategies using the same basic 
components, 3D printed BCP and DAR16-II to functionalise BCP surface.   
  
 
The main conclusions drawn regarding each aim were as follows: 
 
1. To investigate the effect of pore size and geometry in functionalizing 3D printed 
BCP scaffolds: 
BCP scaffolds printed with two different pore sizes and geometries; round (800µm) 
and square (400µm) had no effect on bone regeneration in a rabbit calvaria model.  
There was no significant difference in the total bone developed as well as the bone in 
contact formation.  There was no adverse reaction development thus confirming the 





2. To determine if DAR16-II can be used as a proactive coating matrix for BCP 
scaffolds: 
Coating the BCP scaffolds with DAR16-II enhanced the total bone formation in vivo.  
Bone in contact was significantly increased with DAR16-II coating (p<0.05).  The 
experiment was terminated after 8 weeks of implantation and this reflects the long-
term effect of adding the coating factor the BCP scaffolds.  
 
3. To investigate the biological effect of DAR16-II in vitro at the cell level on 
osteogenesis and angiogenesis: 
a) BCP scaffolds coated with DAR16-II significantly preserved MSCs 
viability up to day 42 compared to non-coated scaffolds (p<0.05).  .  
b) DAR16-II did not induce neither osteogenic nor angiogenetic 
differentiation in MSCs.  In addition, no mineralization effect of DAR16-II 
was detected when MSCs mesenspheres were used as a more pure stem 
cell MSC model.  
Therefore, DAR16-II can be used to augment the BCP effect in enhancing cell 
attachment and viability at the implanted site.  The enhanced proliferation 
during the experiment reflected the preferable cellular environment provided 
by DAR16-II.  The DAR16-II coating provides an ECM-like matrix that 









c) DAR16-II induced angiogenetic effects and cell attachment:  
i. Culturing HUVECs with DAR16-II significantly promoted EC 
spreading (p<0.0001).  In addition, DAR16-II significantly increased 
the tubular length (p<0.01) and the number of developed nodes 
(p<0.001) in Matrigel assay.  Moreover, DAR16-II induced migratory 
phenotype in HUVEC as indicated by its more pronounced cell 
projections.  The DAR16-II angiogenic effect is most likely activated 
through the expression of ENG, SEPINE1 and ACTB and the 
downregulation of VEGF receptors KDR and Flt1.  
 
ii. DAR16-II significantly induced THP-1 cell attachment (p<0.001).  
However DAR16-II did not induce molecular changes after 48 h of 
exposure.  This negative result is assumed to be related to the culturing 
conditions used in this study.  Thus the required cytokines for THP-1 
polarizations were not added to culture.  
 
Using DAR16-II coating can induce vascularization at the implanted site by activating 
endothelial cell migration.  This activation might be mediated by ENG and SERPINE1 
and TGF-β pathway.  Also, DAR16-II induced inflammatory cell attachment which 
suggests that it provides a supporting environment for cell attachment and interaction 




• The method of using DAR16-II as a coating matrix is convenient for clinical 
application regarding the handling and the time required.  
• The fact that a specific motif can be designed and incorporated within the peptide 
sequence can expand the range of clinical application to induce a specific 
biological response. 
• Further studies are required to optimise the culturing of inflammatory cells, 
macrophages in particular in order to investigate if DAR16-II has an 








6.2 Future Work 
The results of this study give rise to further questions that require investigations both in 
vivo and in vitro:  
• Proteomic analysis of protein changes in HUVECs in response to DAR16-II (the 
experiment was conducted and cell pellets are awaiting analysis). 
• The angiogenic effects of DAR16-II require a specific model to study the effect of 
the peptides on angiogenesis in vivo.   
• qRT-PCR validation of the genes of interest being expressed by DAR126-II in 
order to confirm the array results. 
• A microscopical study of the DAR16-II coating using electron microscopy (SEM) 
and RAMAN spectroscopy to assess the coating topography and surface 
chemistry. 
• Examination of the effectiveness of the DAR16-II matrix bonding with the 
ceramic surface by X-ray photoelectron spectroscopy. 
• Investigation of the effect of DAR16-II on polarization and angiogenic 
differentiation markers by qRT-PCR using a more appropriate and physiological 
model of monocytes and macrophages. 

















The gene list 
Gene	  name	  	   Abbreviation	  	  
Angiogenin	   ANG	  
Angiopoietin	  1	   ANGPT1	  
Angiopoietin	  2	   ANGPT2	  
Alanyl	  aminopeptidase	   ANPEP	  
Thymidine	  phosphorylase	   TYMP	  
Fibroblast	  growth	  factor	  1	   FGF1	  
Fibroblast	  growth	  factor	  2	   FGF2	  (BFGF)	  
Vascular	  endothelial	  growth	  factor	  D	   VEGFD	  
Fms	  related	  tyrosine	  kinase	  1	   FLT1	  (VEGFR1)	  
Jagged	  1	   JAG1	  
Kinase	  insert	  domain	  receptor	   KDR	  (VEGFR3)	  
Neuropilin	  1	   NRP1	  
Neuropilin	  2	   NRP2	  
Placental	  growth	  factor	   PGF	  
Vascular	  endothelial	  growth	  factor	  A	   VEGFA	  
Vascular	  endothelial	  growth	  factor	  B	   VEGFB	  
Vascular	  endothelial	  growth	  factor	  C	   VEGFC	  
connective	  tissue	  growth	  factor	   CTGF	  
Ephrin	  A1	   EFNA1	  
Ephrin	  B2	   EFNB2	  
Epidermal	  growth	  factor	   EGF	  
EPH	  receptor	  B4	   EPHB4	  
Fibroblast	  growth	  factor	  receptor	  3	   FGFR3	  
Hepatocyte	  growth	  factor	   HGF	  
Insulin	  like	  growth	  factor	  1	   IGF1	  
Integrin	  subunit	  beta	  3	   ITGB3	  
Platelet	  derived	  growth	  factor	  subunit	  A	   PDGFA	  
Sphingosine-­‐1-­‐phosphate	  receptor	  1	   S1PR1	  
TEK	  receptor	  tyrosine	  kinase	   TEK	  (TIE2)	  
Transforming	  growth	  factor	  alpha	   TGFA	  
Transforming	  growth	  factor	  beta	  1	   TGFB1	  
Transforming	  growth	  factor	  beta	  2	   TGFB2	  
Transforming	  growth	  factor	  beta	  receptor	  1	   TGFBR1	  (ALK5)	  
Adhesion	  G	  protein-­‐coupled	  receptor	  B1	   ADGRB1	  
Collagen	  type	  IV	  alpha	  3	  chain	   COL4A3	  
C-­‐X-­‐C	  motif	  chemokine	  ligand	  8	   CXCL8	  
Neuropilin	  1	   NRP1	  
Neuropilin	  2	   NRP2	  
C-­‐C	  motif	  chemokine	  ligand	  11	   CCL11	  
C-­‐C	  motif	  chemokine	  ligand	  2	   CCL2	  
Cadherin	  5	   CDH5	  
Collagen	  type	  XVIII	  alpha	  1	  chain	   COL18A1	  
Connective	  tissue	  growth	  factor	   CTGF	  
Endoglin	   ENG	  
Erb-­‐b2	  receptor	  tyrosine	  kinase	  2	   ERBB2	  
Fibronectin	  1	   FN1	  
Integrin	  subunit	  alpha	  V	   ITGAV	  
Integrin	  subunit	  beta	  3	   ITGB3	  




Thrombospondin	  1	   THBS1	  
Thrombospondin	  2	   THBS2	  
Angiopoietin	  like	  4	   ANGPTL4	  
Coagulation	  factor	  III	   F3	  
Platelet	  and	  endothelial	  cell	  adhesion	  molecule	  
1	  
PECAM1	  
Platelet	  factor	  4	   PF4	  
Prokineticin	  2	   PROK2	  
Serpin	  family	  E	  member	  1	   SERPINE1	  (PAI-­‐
1)	  
Serpin	  family	  F	  member	  1	   SERPINF1	  
Leukocyte	  cell	  derived	  chemotaxin	  1	   LECT1	  
Leptin	   LEP	  
Matrix	  metallopeptidase	  14	   MMP14	  
Matrix	  metallopeptidase	  2	   MMP2	  
Matrix	  metallopeptidase	  9	   MMP9	  
Plasminogen	  activator,	  urokinase	   PLAU	  
Plasminogen	   PLG	  
TIMP	  metallopeptidase	  inhibitor	  1	   TIMP1	  
TIMP	  metallopeptidase	  inhibitor	  2	   TIMP2	  
TIMP	  metallopeptidase	  inhibitor	  3	   TIMP3	  
C-­‐X-­‐C	  motif	  chemokine	  ligand	  1	   CXCL1	  
C-­‐X-­‐C	  motif	  chemokine	  ligand	  10	   CXCL10	  
C-­‐X-­‐C	  motif	  chemokine	  ligand	  5	   CXCL5	  
C-­‐X-­‐C	  motif	  chemokine	  ligand	  6	   CXCL6	  
C-­‐X-­‐C	  motif	  chemokine	  ligand	  9	   CXCL9	  
Endothelin	  1	   EDN1	  
Interferon	  alpha	  1	   IFNA1	  
Interferon	  gamma	   IFNG	  
Interleukin	  1	  beta	   IL1B	  
Interleukin	  6	   IL6	  
Midkine	  (neurite	  growth-­‐promoting	  factor	  2)	   MDK	  
Tumor	  necrosis	  factor	   TNF	  
Hypoxia	  inducible	  factor	  1	  alpha	  subunit	   HIF1A	  
Nitric	  oxide	  synthase	  3	   NOS3	  
Sphingosine	  kinase	  1	   SPHK1	  
AKT	  serine/threonine	  kinase	  1	   AKT1	  
Heparanase	   HPSE	  
Inhibitor	  of	  DNA	  binding	  1,	  HLH	  protein	   ID1	  
Notch	  4	   NOTCH4	  
Prostaglandin-­‐endoperoxide	  synthase	  1	   PTGS1	  
Tyrosine	  kinase	  with	  immunoglobulin	  like	  and	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